Page last updated: 2024-08-21

thiazoles and mirabegron

thiazoles has been researched along with mirabegron in 497 studies

Research

Studies (497)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (0.60)	29.6817
2010's	339 (68.21)	24.3611
2020's	155 (31.19)	2.80

Authors

Authors	Studies
Maruyama, T; Matsui, T; Miyata, K; Nagase, I; Sasamata, M; Sato, S; Takasu, T; Uchida, H; Ukai, M; Yamaguchi, O	1
Lazzeri, M	1
Alewijnse, AE; Michel, MC; Vrydag, W	1
Tyagi, P; Tyagi, V	1
Chancellor, M; Tyagi, P; Tyagi, V	1
Iwatsubo, T; Krauwinkel, W; Meijer, J; Miyashita, A; Nagata, M; Schaddelee, M; Sekiguchi, M; Suzuki, K; Takusagawa, S; Usui, T; van Gelderen, M; van Lier, JJ	1
Beld, Cv; Gelderen, Mv; Meijer, J; Takusagawa, S; Teijlingen, Rv; Usui, T	1
Gras, J	1
Bhide, AA; Digesu, GA; Fernando, R; Khullar, V	1
Baumgartner, R; Behr-Roussel, D; Giuliano, F; Gorny, D; Ney, P; Oger-Roussel, S; Tasler, S	1
Iwatsubo, T; Miyashita, A; Takusagawa, S; Uehara, S; Usui, T; Yajima, K	1
Sasamata, M; Seki, N; Suzuki, M; Ukai, M	1
Ellsworth, P	1
Elser, DM	1
Gillespie, JI; Guerard, M; Guilloteau, V; Korstanje, C; Lluel, P; Palea, S	1
Wyndaele, JJ	1
Iwatsubo, T; Miyashita, A; Takusagawa, S; Usui, T	1
Opar, A	1
Drogendijk, T; Eltink, C; Grunenberg, N; Iitsuka, H; Kerbusch, V; Kowalski, D; Lee, J; Matsushima, H; Meijer, J; Moy, S; Sawamoto, T; Schaddelee, M; van Gelderen, M; van Marle, S; Zhang, W	1
Aizawa, N; Homma, Y; Igawa, Y	2
Eltink, C; Kerbusch, V; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; van Dijk, J; van Gelderen, M; van Marle, S	1
Andersson, KE; Hood, B	1
Auerbach, S; Calhoun, A; Herschorn, S; Lee, M; Martin, N; Nitti, VW	1
de Koning, P; Goldwater, R; Kaibara, A; Keirns, JJ; Kowalski, DL; Lee, JH; Malik, M; Moy, SS; Mujais, SK; Schaddelee, MP; van Gelderen, EM; Yen, M	1
Belavic, JM	2
Amarenco, G; Angulo, JC; Boerrigter, P; Cambronero, J; Chapple, C; Drogendijk, T; Høye, K; Khullar, V; Milsom, I; Radziszewski, P; Rechberger, T; Wooning, M	1
Chapple, CR; Cummings, J; Dorrepaal, C; Drogendijk, T; Kaplan, SA; Klecka, J; Martin, N; Mitcheson, D	1
Cornu, JN; Novara, G	1
Dickinson, J; Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Kupčová, V; Lasseter, K; Lewand, M; Meijer, J; Morton, R; Moy, S; Riff, D; Sawamoto, T; Schaddelee, M; van Gelderen, M	1
Kosaka, T; Kuwahara, Y; Mishima, J; Nakamura, K; Otsuki, H; Tsukamoto, T	1
Hatanaka, T; Kaku, S; Ohtake, A; Sato, S; Someya, A; Suzuki, M; Ueshima, K; Ukai, M; Watanabe, M	1
Hussar, DA; Martinez, LN	1
Hatanaka, T; Ohtake, A; Sasamata, M; Sato, S; Someya, A; Suzuki, M; Ueshima, K; Ukai, M; Watanabe, M	1
Andersson, KE; Bouchelouche, K; Bouchelouche, P; Korstanje, C; Nordling, J; Svalø, J	1
Muller, N	1
Amarenco, G; Chapple, CR; Everaert, K; Liehne, J; López Aramburu, MA; Lucas, M; Ridder, A; Snijder, R; Vik, V; Yamaguchi, O	1
Andersson, KE; Martin, N; Nitti, V	1
Boerrigter, P; Bosman, B; Chapple, CR; Drogendijk, T; Dvorak, V; Radziszewski, P; Ridder, A; Van Der Putten-Slob, I; Van Kerrebroeck, P; Wyndaele, JJ; Yamaguchi, O	1
Grunenberg, N; Keirns, J; Kerbusch, V; Kowalski, D; Lee, J; Moy, S; Sawamoto, T; van Gelderen, M; Zhang, W	1
Cornu, JN	1
Kashyap, M; Tyagi, P	1
Hussar, DA	2
Iwatsubo, T; Kerbusch, V; Li, Q; Miyashita, A; Nemoto, H; Takahashi, Y; Takusagawa, S; Ushigome, F; Usui, T	1
Hantsbarger, G; Lewis, RA; Martin, NE; Novack, GD; Rasmussen, S; Sheth, N; Swearingen, D; Vogel, R	1
Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Lee, J; Marion, A; Meijer, J; Moy, S; Roy, M; Sawamoto, T; Takusagawa, S; van Gelderen, M	1
Devlin, N; Hakimi, Z; Herdman, M; Hoyle, C; Nazir, J; Odeyemi, IA; Pavesi, M	1
Andersson, KE	3
Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Herschorn, S; Khullar, V; Martin, NE; Nitti, VW; Siddiqui, E; van Kerrebroeck, P	1
Fakhoury, A; He, W; Martin, NE; Mitcheson, DH; Nitti, VW; Rosenberg, S	1
Dickinson, J; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; Tretter, R; van de Wetering, J; van Gelderen, M	1
De Nunzio, C; Puccini, F; Tubaro, A	1
Barkin, J; Castro-Diaz, D; Espuna-Pons, M; Frankel, JM; Gousse, AE; Gunther, A; Herschorn, S; Martin, N; Stölzel, M; Van Kerrebroeck, P	1
Sanford, M	1
de Groat, WC	1
Hatanaka, T; Masuda, N; Ohtake, A; Sato, S; Someya, A; Suzuki, M; Ueshima, K; Ukai, M; Watanabe, M	1
Andersson, KE; Hood, B; Koslov, D; Nomiya, M; Sawada, N; Zarifpour, M	1
Cui, Y; Yan, H; Yang, C; Zhang, Y; Zong, H	1
Dmochowski, R; Kaufman, M; Osborn, D; Reynolds, WS; Suarez, O	1
Caremel, R; Corcos, J; Loutochin, O	1
Lindo, FM	1
Drake, MJ; Paton, JF; Pickering, AE; Sadananda, P	1
Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Khullar, V; Martin, NE; Wooning, M	1
Imran, M; Najmi, AK; Tabrez, S	1
Nakanishi, S	1
Cardozo, L; Chapple, CR; Michel, MC; Nitti, VW; Siddiqui, E	1
Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M	1
Bastide, C; Bruyere, F; Caremel, R; Castel-Lacanal, E; Cornu, JN; Guy, L; Karsenty, G; Kerdraon, J	1
Aballea, S; Desroziers, K; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, I; Siddiqui, E	1
Siddiqui, E	1
Blauwet, MB; Chapple, CR; Herschorn, S; Khullar, V; Nitti, VW; Siddiqui, E; van Kerrebroeck, P; Wyndaele, JJ	1
Gotoh, M; Homma, Y; Igawa, Y; Ikeda, Y; Kakizaki, H; Marui, E; Nishizawa, O; Ohkawa, S; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M	1
Bassi, P; Bientinesi, R; D'Agostino, D; Gulino, G; Racioppi, M; Sacco, E; Tienforti, D; Vittori, M	1
Challacombe, B; Dasgupta, P; Ficarra, V; Iannetti, A; Novara, G; Rossanese, M	1
Auerbach, S; Blauwet, MB; Cardozo, L; Castro-Diaz, D; Nitti, VW; Siddiqui, E; Wagg, A	1
Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R	1
Candiani, M; Cardozo, L; Cola, A; Colacurci, N; Del Deo, F; Ferrero, S; Leone Roberti Maggiore, U; Salvatore, S; Sileo, F; Torella, M	1
Auerbach, S; Blauwet, MB; Chapple, CR; Herschorn, S; Milsom, I; Nitti, VW; Radziszewski, P; Walters, C	1
Brooks, A; Dickinson, J; Dorrepaal, C; Gangaram-Panday, S; Krauwinkel, W; Meijer, J; Tretter, R; van Gelderen, M	1
Kulik-Rechberger, B; Miotła, P; Rechberger, T; Wróbel, A	1
Hnatkova, K; Keirns, JJ; Kowalski, D; Malik, M; Van Gelderen, EM	1
Mayr, CA; Shepherd, JP	1
Aoki, Y; Arima, A; Miyamae, Y; Nakagawa, S; Onishi, Y; Schneidkraut, MJ; Yuno, K; Zaizen, K	1
Chapple, C	1
Balachandran, A; Basu, M; Curtiss, N; Duckett, J	1
Blauwet, MB; Chapple, CR; Huang, M; Kaplan, SA; Khullar, V; Mitcheson, D; Siddiqui, E	1
Blauwet, MB; Chapple, C; Frankel, J; Herschorn, S; Kaper, M; Khullar, V; Nitti, VW; Siddiqui, E	1
Bu, SY; Cao, CX; Duan, X; Peng, CD; Wang, KJ; Wu, T	1
Ginsberg, DA; Goldmark, E; Niver, B	1
Kubota, Y; Kuo, HC; Kuroishi, K; Lee, KS; Na, Y; Nakaji, S; Sood, R	1
Fukuta, F; Ichihara, K; Iwasawa, A; Masumori, N; Tanaka, Y; Tsukamoto, T	1
Constantinescu, CC; Mirbolooki, MR; Mukherjee, J; Pan, ML; Schade, KN	1
Alexandre, EC; Antunes, E; Calmasini, FB; Candido, TZ; D'Ancona, CA; De Nucci, G; de Oliveira, MA; Mónica, FZ; Silva, D	1
Garnham, A; Hakimi, Z; Nazir, J; Odeyemi, IA; Posnett, J; Walker, A	1
Aballéa, S; Garnham, A; Hakimi, Z; Maman, K; Nazir, J; Odeyemi, IA; Thokagevistk, K; Toumi, M	1
Bragg, R; Hebel, D; Pitlick, JM; Vouri, SM	1
Chatman, K; Cypess, AM; Doria, A; English, J; Franquet Elía, E; Kahn, PA; Kessler, SH; Kolodny, GM; Roberts-Toler, C; Trauger, SA; Weiner, LS	1
Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M	2
Hashizume, K; Kakizaki, H; Kita, M; Kobayashi, S; Matsumoto, S; Okazaki, S; Wada, N	1
Becher, KF; Sieber, CC	1
Blauwet, MB; Castro-Diaz, D; Chapple, CR; Delgado-Herrera, L; Hakimi, Z; Lau, W; Mujais, S	1
Funahashi, Y; Gotoh, M; Matsukawa, Y; Takai, S; Yamamoto, T	1
Boudy, AS; Thubert, T	1
Balachandran, AA; Duckett, JR	1
Hagiwara, M; Hasegawa, M; Ishioka, K; Kikuchi, E; Maeda, T; Miyajima, A; Miyazaki, Y; Oya, M; Shinojima, T	1
Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M	1
Cohen, AF; Goulooze, SC; Rissmann, R	1
Sun, L; Wei, P; Zhou, F; Zhou, Y; Zou, Q	1
Calvi, P; D' Agostino, G; Maria Condino, A	1
Abrams, P; Kay, R; Martina, R; Ridder, A; van Maanen, R	1
Cernecka, H; de Jong, IJ; Elzinga, CR; Kersten, K; Korstanje, C; Maarsingh, H; Michel, MC; Schmidt, M	1
Bridgeman, MB; Dalal, KS	1
Akiyama, Y; Fujimura, T; Fukuhara, H; Furuta, A; Homma, Y; Ichihara, K; Igawa, Y; Kamei, J; Kume, H; Niimi, A	1
Cardozo, L; Srikrishna, S; Thiagamoorthy, G	1
Alexandre, EC; Antunes, E; Claudino, MA; Costa, FF; da Silva, FH; de Nucci, G; Fertrin, KY; Franco-Penteado, CF; Leiria, LO; Mónica, FZ; Renno, A	1
Hanuš, T; Krhut, J; Martan, A; Mašata, J; Švabík, K	1
Balachandran, A; Basu, M; Duckett, J	1
Amarenco, G; Angulo, JC; Blauwet, MB; Hakimi, Z; Khullar, V; Nazir, J; Odeyemi, IA	1
Cardozo, L; Giarenis, I; Robinson, D	1
Sidaway, P	3
Karmarkar, R; Khullar, V	1
Aballéa, S; Briquet, B; Garnham, A; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, IA	1
de Greef-van der Sandt, I; Dorrepaal, C; Martina, R; Newgreen, D; Ridder, A; Schaddelee, M; van Maanen, R	1
Chapple, CR; Ferrero, S; Nitti, VW; Rosa, GM; Saleem, T; Wagg, A	1
Alexandre, EC; Antunes, E; Calmasini, FB; da Silva, KP; Ferreira, R; Kiguti, LR; Mónica, FZ; Pupo, AS; Ribeiro, CA; Silva, FH	1
Turpen, HC; Zimmern, PE	1
Pannek, J; Wöllner, J	1
Igawa, Y; Ikeda, Y; Marui, E; Nishizawa, O; Ohkawa, S; Takeda, M; Yamaguchi, O	1
Kelleher, C; Malde, S; Nowers, J; Pindoria, N; Sahai, A; Taylor, C	1
Hanuš, T; Krhut, J; Martan, A; Švabík, K; Zachoval, R; Zvara, P	1
Balachandran, A; Duckett, J	2
Berner, T; Castro-Diaz, D; Kelleher, C; Nitti, VW; Siddiqui, E; Wagg, A	1
Blais, AS; Bolduc, S; Genois, L; Moore, K; Nadeau, G	1
Farrié, M; Gillespie, J; Junquero, D; Le Grand, B; Monjotin, N; Vergnolle, N	1
Arber, M; Fleetwood, K; Freemantle, N; Ginsberg, DA; Glanville, J; Khalaf, K; Loveman, C; McCool, R; Ni, Q	1
Gravas, S; Michel, MC	1
Athanasiou, S; Cambronero, J; Chapple, C; Drake, MJ; Esen, AA; Herholdt, C; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Saleem, T; Siddiqui, E; Stölzel, M	1
Cardozo, L; Robinson, D; Thiagamoorthy, G	1
Angulo, JC; Liu, S; Luo, X; Peral, C; Ramos, J; Rejas, J; Sánchez-Ballester, F; Snedecor, SJ; Sudharshan, L	1
Balligand, JL	1
Cheeran, B; Fletcher, C; Murchison, AG	1
Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Grise, P; Hakimi, Z; Hemsted, C; Herschorn, S; Huang, M; MacDiarmid, S; Nazir, J; Saleem, T; Siddiqui, E; Stölzel, M	1
Morosetti, C; Vecchioli Scaldazza, C	1
Gur, S; Hellstrom, WJ; Kadowitz, PJ; Peak, T; Sikka, SC; Yafi, FA	1
Alcántara-Montero, A	1
Griebling, TL	3
De Wachter, S; Eastham, J; Gillespie, J; Persyn, S; Wyndaele, JJ	1
Aoki, K; Fujimoto, K; Goto, D; Hirayama, A; Hosokawa, Y; Matsumoto, Y; Matsushita, C; Miyake, M; Tanaka, N; Torimoto, K; Yamada, A	1
Altman, D; Christensson, AA; Elmér, C; Flam, B; Kallner, HK	1
Campbell, NL; Klein, RW; Klein, TM; Ng, DB; Perk, S; Posta, LM; Wielage, RC; Yuran, T	1
Agüero, J; Barberá, JA; Campelos, P; Castellá, M; Fernández-Friera, L; Fernández-Jiménez, R; Fuster, V; García-Álvarez, A; García-Lunar, I; García-Prieto, J; García-Ruiz, JM; Ibañez, B; Nuño-Ayala, M; Peinado, VI; Pereda, D; Pizarro, G; Sabaté, M; Sandoval, E; Santiago, E; Sanz-Rosa, D; Sierra, F	1
Groen-Wijnberg, M; Kerbusch, V; Krauwinkel, W; Meijer, J; Tretter, R; van Dijk, J; van Gelderen, M; Zhang, W	1
Imamura, T; Ishizuka, O; Minagawa, T; Nagai, T; Nakazawa, M; Ogawa, T; Saito, T; Suzuki, T; Yokoyama, H	1
Kakizaki, H; Shimizu, N; Shimizu, T; Takai, S; Tyagi, P; Wada, N; Yoshimura, N	1
Inoue, M; Ohyama, K	1
Asai, A; Kakoki, K; Matsuo, T; Miyata, Y; Ohba, K; Sakai, H; Yuzuriha, M	1
Abrams, P; Kay, R; Kelleher, C; Martan, A; Mincik, I; Newgreen, D; Paireddy, A; Ridder, A; Staskin, D; van Maanen, R	1
Altman, D; Andersson, KE; Elmér, C; Kallner, HK	1
Cruz, F	1
Campbell, NL; Klein, RW; Klein, TM; Ng, DB; Perk, S; Perkins, A; Posta, LM; Wielage, RC; Yuran, T	1
Kasashima, Y; Namiki, N; Sako, K; Uchida, S; Yasuji, T; Yoshihara, K	1
Hashizume, K; Iuchi, H; Kakizaki, H; Kita, M; Matsumoto, S; Wada, N	1
Kato, D; Katoh, T; Kuroishi, K; Kuwamoto, K	1
Furuse, H; Kageyama, S; Kitagawa, M; Matsumoto, R; Nagae, H; Otsuka, A; Ozono, S; Suzuki, T	1
Alexandre, EC; Antunes, E; Calmasini, FB; Candido, TZ; da Silva, CPV; da Silva, FH; de Oliveira, MG; Mónica, FZ	1
Kuo, HC; Liao, CH	3
Hatta, T; Iitsuka, H; Kaibara, A; Katashima, M; Kuroishi, K; Moy, S; Nomura, Y; Sawamoto, T; Toyoshima, J	1
Kato, D; Kuroishi, K; Nozawa, Y; Tabuchi, H	1
Kinjo, M; Nutahara, K; Sekiguchi, Y; Yoshimura, Y	1
Blais, AS; Bolduc, S; Genois, L; Moore, K; Morin, F; Nadeau, G	1
Cantaluppi, S; Finazzi Agrò, E; Ghezzi, F; Leone Roberti Maggiore, U; Serati, M; Sorice, P	1
Axelsson, A; Boesgaard, S; Bundgaard, H; Fry, NA; Gustafsson, F; Hartvig Thomsen, J; Hasselbalch, R; Iversen, K; Kofoed, KF; Køber, L; Rasmussen, HH; Sørgaard, M; Valeur, N	1
Chapple, CR; Siddiqui, E	1
Kamai, T; Kobayashi, M; Nukui, A	1
Abbass, IM; Bradt, P; Caplan, EO; Chan, WM; Collins, JM; Kristy, R; Ng, DB; Schermer, CR; Suehs, BT	1
Balligand, JL; Michel, LYM	1
Hanus, T; Krhut, J; Martan, A; Masata, J; Svabik, K; Zachoval, R	1
Gur, S; Kaya, E; Oral, DY; Ozakca, I; Sikka, SC	1
Ikeda, Y; Ohkawa, S; Yamaguchi, O	1
Bowditch, S; Chapple, CR; Fatoye, F; Guelfucci, F; Hakimi, Z; Khemiri, A; Nazir, J; Siddiqui, E; Wagg, A	1
Wein, AJ	6
Seftel, AD	2
Kirby, J; Obloza, A; Toozs-Hobson, P; Yates, D	1
Legrand, F; Moyson, J; Quackels, T; Roumeguère, T; Vanden Bossche, M	1
Balykina, YE; Kolbin, AS; Proskurin, MA; Vilyum, IA	1
Hashim, H; Sharaf, A	1
Berling, M; Fatoye, F; Hakimi, Z; McCrea, C; Nazir, J; Ramos, B; Wagg, A	1
Cardozo, L; Izett, M; Robinson, D; Thiagamoorthy, G; Zacche, M	1
Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Herschorn, S; Huang, M; MacDiarmid, S; Siddiqui, E; Stoelzel, M	1
Bunniran, S; Davis, C; Kristy, R; Ng, D; Schermer, CR; Suehs, BT; Uribe, C	1
Chaudhari, S; Kish, J; Kowalski, J; Lee, W; Murray, B; Sussman, D; Yehoshua, A	1
Krivoborodov, GG; Tur, EI	1
Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R	1
Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M	1
Korstanje, C; Sato, S; Schneidkraut, MJ; Suzuki, M; Ukai, M; Yan, GX; Yuno, K	1
Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY	1
Itai, S; Iwao, Y; Katakawa, Y; Kimura, SI; Matsuzaki, N; Mimura, H; Murayama, D; Yamamoto, Y	1
Almodóvar Carretón, MJ; Barreda Velázquez, C; Jamart Sánchez, L; Maestro Nombela, A; Saavedra Quirós, V	1
Antunes, E; Bonilla-Becerra, SM; Calmasini, FB; de Oliveira, MG; Rojas-Moscoso, JA; Zanesco, A	1
Kaumann, AJ; Lee, XW; Michel, MC; Mo, W; Molenaar, P	1
Collins, C; Kerbusch, V; Korstanje, C; Meijer, J; Stölzel, M; van Gelderen, M	1
Fialkov, J; Herschorn, S; Schermer, CR; Staskin, D; Tu, LM; Walsh, T	1
Devlin, N; Drake, MJ; Hakimi, Z; Herdman, M; Huang, M; MacDiarmid, S; Nazir, J; Pavesi, M; Siddiqui, E	1
Brucker, BM; Chapple, CR; Drake, MJ; Fleetwood, K; Ginsberg, DA; Glanville, JM; Hepp, Z; James, D; McCool, R; Nitti, VW	1
Choo, MS; Kim, A; Shin, JH	1
Falconer, C; Hakimi, Z; Herschorn, S; Kelleher, C; Mueller, ER; Paireddy, A; Ridder, A; Robinson, D; Staskin, D; Stoelzel, M; van Maanen, R; Wang, J	1
Kato, D; Tabuchi, H; Uno, S	2
Hodgkinson, L	1
Espinosa, R; Gooch, K; Johnson, SJ; Ng, DB; Walker, D	1
Engle, JA; Fair, C	1
Fan, A; Kato, D; Kimura, T; Uno, S; Van Schyndle, J	1
Araklitis, G; Cardozo, L	1
Kato, D; Kuroishi, K; Nozawa, Y; Tabuchi, H; Yoshida, M	1
Foley, S; Kool-Houweling, L; Nazir, J; Peters, J; Scrine, L; Wagg, AS	1
Choudhury, N; Drake, MJ; Gibson, W; Huang, M; MacDiarmid, S; Siddiqui, E; Stölzel, M	1
Geoffrion, R	2
Konishi, K; Takusagawa, S; Tenmizu, D	1
Chapple, C; Gacci, M; Gravas, S; Kaplan, SA; McVary, KT; Moncada, I; Morgia, G; Russo, GI; Sebastianelli, A; Serni, S	1
Apostolidis, A	1
Bengtsson, T; da Silva Junior, ED; Dehvari, N; Hutchinson, DS	1
Choudhury, N; Foley, S; Freeman, R; Grill, R; Huang, M; Kachlirova, Z; Rosa Arias, J; Stari, A; Vicente, E	1
Hovda, LR; Schmid, RD	1
Baltogiannis, D; Dimitriadis, F; Filiponi, M; Giannakis, J; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A	1
Benedetti Panici, P; D'Oria, O; Faiano, P; Muzii, L; Schiavi, MC; Zullo, MA	1
Hanus, T; Horcicka, L; Krhut, J; Martan, A; Svabík, K; Zachoval, R; Zvara, P	1
Kasyan, GR; Pushkar, DY; Sukhikh, SO	1
Chen, SF; Kuo, HC	1
Matsuo, T; Miyata, Y; Nakamura, T; Sakai, H; Satoh, K	1
Baccino, D; Barra, F; Brunelli, C; Ferrero, S; Rosa, GM; Scala, C; Valbusa, A	1
Chang, HM; Chang, YC; Chen, HL; Chen, TC; Huang, WH; Juan, YS; Lee, HY; Pan, HF; Wang, YL; Wu, CM	1
Bangal, MN; Deshmukh, DG; Mathad, VT; Medhane, VJ; Patekar, MR	1
Filipe, TP; Marques, JG	1
Chapple, CR; Frankel, JM; Gratzke, C; Herschorn, S; Paireddy, A; Ridder, AM; Robinson, D; Stoelzel, M; van Maanen, R; Weber, MA; White, WB	1
Bílková, K; Borovička, V; Krhut, J; Míka, D; Mokriš, J; Sýkora, R; Zachoval, R	1
Antunes Lopes, T; Cornu, JN; Delongchamps, NB; Geavlete, B; Marcelissen, T; Rahnama'i, MS; Rashid, T; Rieken, M	1
Azumi, M; Banjo, H; Hori, J; Kakizaki, H; Kita, M; Tamaki, G; Tsuchida, M; Wada, N; Watanabe, M	1
Alexandre, EM; Antunes, E; Lescano, CH; Mendes-Silvério, CB; Mónica, FZ	1
Fialkov, J; Gooch, K; Herschorn, S; Schermer, CR; Staskin, D; Tu, LM; Walsh, T	1
Chang, SL; Dupree, JM; Kirk, PS; Modi, PK; Singer, EA; Wang, Y	1
Elterman, D; Gomes, T; Minhas, R; Tadrous, M	1
Kuo, HC; Lee, CL	1
Aballéa, S; Chapple, C; Hakimi, Z; Kelleher, C; Maman, K; Nazir, J; Siddiqui, E; Zur, R	1
Marcelissen, TAT; Van Koeveringe, GA	1
Carlson, KV; Deal, AS; Gemmen, E; Gooch, KL; Kristy, RM; Nair, KV; Oakkar, EE; Park, J; Rovner, ES; Schermer, CR	1
Bae, JH; Cho, S; Cho, SY; Choi, H; Jeon, BJ; Lee, KC; Park, JY; Tae, BS	1
Kuo, HC; Wang, CC	1
Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ	1
Deeks, ED	1
Chuang, YC; Shen, YC; Wang, HJ	1
Gibson, W; Wagg, A	1
Kuo, HC; Lee, YK	1
Anker, S; Balligand, JL; Brito, D; Brosteanu, O; Casadei, B; Edelmann, F; Filippatos, G; Gerber, BL; Gruson, D; Hasenclever, D; Ikonomidis, I; Lhommel, R; Mahmod, M; Neubauer, S; Persu, A; Piechnik, S; Pieske, B; Pieske-Kraigher, E; Pinto, F; Ponikowski, P; Pouleur, AC; Senni, M; Trochu, JN; Van Overstraeten, N; Wachter, R	1
Staskin, DR	1
Dimitriadis, F; Filiponi, M; Giannakis, J; Mamoulakis, C; Skouros, S; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A	1
Carmosino, M; Gerbino, A; Milano, S; Procino, G; Schena, G; Svelto, M	1
Iatsyna, O; Kostyev, F; Vernygorodskyi, S	1
Biagioni, MC; Brucker, BM; Feigin, A; Frucht, S; Gilbert, R; Kaufmann, H; Malacarne, DR; Nitti, VW; Palma, JA; Palmerola, R; Peyronnet, B; Rosenblum, N; Sussman, RD; Vurture, G	1
Fernández-Jiménez, R; Galán-Arriola, C; García-Álvarez, A; García-Prieto, J; García-Ruiz, JM; Ibanez, B; Lobo-Gonzalez, M; Piñero, A; Pizarro, G; Rossello, X; Sánchez-González, J; Sanz-Rosa, D; Vilchez, JP	1
Bayrak, O; Bulut, E; Solakhan, M	1
Alexander, CM; Confides, AL; Dupont-Versteegden, EE; Finlin, BS; Harfmann, B; Johnson, ZR; Jones, KA; Kasza, I; Kern, PA; Memetimin, H; Sullivan, PG; Vekaria, HJ; Westgate, PM; Zhu, B	1
Cammisotto, PG; Campeau, L; Mossa, A; Nguyen, H; Velasquez Flores, M	1
Ikeda, S; Tajima, H; Yamanishi, T; Yamanishi, Y	1
Ethans, K; Hickling, D; McKibbon, M; Radomski, S; Welk, B	1
Blázquez, AMM; Fatoye, F; González, MH; Guelfucci, F; Hakimi, Z; Khemiri, A; Nazir, J	1
Ueshima, K; Ukai, M	1
Carey, AL; Formosa, MF; Kingwell, BA; La Gerche, A; Loh, RKC; Reutens, AT	1
Farrell, GC; Gillard, J; Horsmans, Y; Leclercq, IA; Poekes, L	1
Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K	2
Bae, JH; Jeong, SJ; Joo, KJ; Kang, TW; Kim, HW; Kim, SW; Kim, YH; Koo, KC; Lee, YG; Shin, DG; Son, H; Song, SH; Woo, SH; Yoo, ES; Yoon, SJ	1
Gooch, KL; Johnston, KM; Khangulov, V; Rumsfeld, JS; Schermer, CR; Szabo, SM; Vonesh, E	1
Kim, JH; Lee, SR; Park, BW	1
Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z	1
Hagiya, H; Kokado, R; Okuno, H; Tomono, K	1
Colomer, MEB; Dolcet, MJL; Fernández-Liz, E; Martínez, AA; Rebull, JO; Tristante, PV	1
Fatoye, F; Hakimi, Z; Nazir, J; Siddiqui, E; Smith, P; Yeowell, G	1
Han, SW; Kim, SH; Kim, SW; Lee, CN; Lee, YS; Park, JS	1
Boer, R; Dmochowski, R; Gillard, KK; Gultyaev, D; Hessami, SH; Kaplan, S; Lister, J; Murray, B; Stanisic, S; Tung, A	1
Kitta, T	1
Arlandis-Guzmán, S; Brenes-Bermúdez, F; Duran, A; Jiménez-Cidre, MA; Mora, AM; Rubio-Rodríguez, D; Rubio-Terrés, C	1
Jiang, YH; Kuo, HC; Wang, CC	1
Korshunova, ES	1
Choo, MS; Shin, JH	1
Sahin, A; Tokuc, E; Topaktas, R; Urkmez, A; Yuksel, OH	1
Eto, M; Itsumi, M; Kajioka, S; Kareman, E; Lee, K; Maki, T; Shiota, M	1
Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Rechberger, T; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ	1
Cantaluppi, S; Coluccia, AC; Ghezzi, F; Giannantoni, A; Gubbiotti, M; Serati, M	1
Okui, N	1
Chiba, K; Fujisawa, M; Okada, K; Tanaka, M	1
Johnston, KM; Lakzadeh, P; Walker, DR	1
Gratzke, C; Siddiqui, E	1
Hofstede, V; Huls, R; Krauwinkel, W; Meijer, J; Niesing, W; van den Beld, C; van den Berg, T	1
Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Sassa, N; Takai, S; Yamamoto, T	1
Deighton, A; Dmochowski, R; Hawkins, N; Johnston, K; Lozano-Ortega, G; Rogula, B; Walker, D	1
Fukuhara, H; Kinjo, M; Okegawa, T; Tambo, M; Yamaguchi, T	1
Feng, M; Huang, T; Jin, J; Li, D; Li, M; Lin, J; Wang, J; Zhao, D; Zhu, W	1
Balcerzak, M; Mikkola, TS; Rahkola-Soisalo, P; Ruotsalainen, J	1
Chen, L; Zhang, Y	1
Altman, D; Elmér, C; Kopp Kallner, H	1
Schneider, MH; Struck, JP	1
Abbasi, M; Hao, L; Khan, MSH; Scott, S; Wang, S; Wu, D; Yang, Y; Zhao, L; Zu, Y	1
Bogusiewicz, M; Kulik-Rechberger, B; Miotla, P; Rechberger, E; Rechberger, T; Wrobel, A; Zietek, A	1
Askin, D; Gur, S; Hamurtekin, Y; Kaya-Sezginer, E; Yilmaz-Oral, D	1
Aydın, M; Bayar, G; Kilinc, MF; Yavuz, A	1
Kaplan, SA	1
Almeida, FG; Bernardo, WM; Sacomani, CAR; Silvinato, A	1
Cao, Y; Chen, Y; Cheng, J; Dong, M; Jing, X; Li, H; Pan, H; Shi, W; Sui, W; Wang, X; Xue, F; Yang, Y; Zhang, C; Zhang, H; Zhang, M; Zhang, Y; Zhou, Q	1
Goosen, TC; Lin, J; Malhotra, B; Tse, S; Yamagami, H	1
De Ridder, D; Hakim, L; Soebadi, MA; Van der Aa, F	1
Gao, Z; Zhou, Z	1
Hansson, F; Kilany, S; Milsom, I; Schiotz, HA; Svensson, M	1
Antunes, E; Bertollotto, GM; Candido, TZ; De Nucci, G; de Oliveira, MG; Kiguti, LRA; Mónica, FZ; Pupo, AS; Rojas-Moscoso, JA	1
Choudhury, N; Foley, S; Freeman, R; Huang, M; Nazir, J; Stari, A	1
Cakir, SS; Culha, MG; Degirmentepe, RB; Homma, Y; Ozbir, S	1
Kadekawa, K; Nishijima, S; Noguchi, K; Sugaya, K; Ueda, T; Yamamoto, H	1
Becher, K; Bojack, B; Ege, S; Kirschner-Hermanns, R; von der Heide, S; Wiedemann, A	1
Jeong, JH; Kim, DW; Kim, JY; Kwon, YB; Lee, HG; Park, CW; Park, ES; Park, YS; Rhee, YS; Shin, DH	1
Becker, M; Blüher, M; Daniel, C; Hauner, H; Mengel, L; Ott, VB; Salb, VK; Serr, I; Tschöp, MH; Weigmann, B	1
Gotoh, M; Matsukawa, Y	1
Chuang, YC; Lee, WC; Shen, YC; Wang, HJ; Wu, TH	1
Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O	1
Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M	1
Inoue, M; Yokoyama, T	1
Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Yamamoto, T	1
Jong, JJ; Kakizaki, H; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O	1
Engel, E; Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A	1
Marcelissen, T; Rademakers, K	1
Hizue, M; Ito, Y; Kadekawa, K; Nishijima, S; Sugaya, K; Yamada, S; Yamagami, H	1
Corbett, HJ; Dobson, E; Fryer, S; Griffiths, M; Kenny, SE; McAndrew, HF; Nicoara, C	1
Baka-Ostrowska, M; Bosman, B; Kjaeer, B; Passier, P; Rittig, S; Stroosma, O; Tannenbaum, S; Tøndel, C; Walle, JV	1
Abi Tayeh, G; Chebel, R; El Helou, E; El Helou, J; Jalkh, G; Labaki, C; Nemr, E	1
Kawahara, T	1
Aydın, M; Bayar, G; Cakmak, S; Kilinc, MF; Kucuk, E; Ofluoglu, Y; Yavuz, A	1
Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D	1
Kociszewski, J; Poleszak, E; Serefko, A; Szopa, A; Wiśniewski, R; Woźniak, A; Wróbel, A	1
Sahin, A; Urkmez, A; Yildirim, C; Yuksel, OH	1
Ader, M; Baskin, AS; Bergman, RN; Brychta, RJ; Cai, H; Cassimatis, TM; Cero, C; Chen, KY; Cypess, AM; Dieckmann, W; Fink, YA; Fletcher, LA; Herscovitch, P; Javitt, NB; Johnson, JW; Kapuria, D; Kelsey, N; Leitner, BP; Linderman, JD; McGehee, S; Millo, CM; O'Mara, AE; Piccinini, F; Rotman, Y; Sater, ZA; Walter, M; Walter, PJ	1
Chen, J; Confides, AL; Dupont-Versteegden, EE; El Khouli, RH; Finlin, BS; Johnson, ZR; Kern, PA; Memetimin, H; Morris, AJ; Sullivan, PG; Vekaria, HJ; Westgate, PM; Zhu, B	2
Fuse, M; Kaga, K; Kageyama, S; Sakata, K; Tokunaga, S; Yamanishi, T; Yokoyama, T	1
Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S	1
Egberts, J; Elzevier, HW; Groenendijk, PM; Kummeling, MTM; Putter, H; van Koeveringe, GA	1
Araklitis, G; Baines, G; Cardozo, L; Flint, R; Robinson, D	1
Alothmani, R; Aronsson, P; Carlsson, T; Patel, B; Perez, F; Winder, M	1
Delfino, K; Dynda, D; El-Zawahry, A; McVary, KT; Petrossian, RA	1
Balsamo, R; Costantini, E; Finazzi Agrò, E; Illiano, E; Natale, F	1
Poza-Barrasús, JL; Valero Fernández, EM; Zubiaur Líbano, C	1
Campbell, NL; Elsouda, D; Griebling, TL; Herschorn, S; Mangel, J; Schermer, CR; Staskin, D	1
Peyronnet, B	1
Flier, JS	1
Clodfelder-Miller, B; McNaught, J; Ness, TJ; Su, X	1
Mandpe, P; Prabhakar, B; Shende, P	1
Aoki, H; Fujio, K; Hori, S; Kosaka, T; Otsuki, H; Uehara, S; Yamasaki, T	1
Gibson, W; Makhani, A; Thake, M	1
Abreu-Mendes, P; Cruz, F; Martins-Silva, C	1
Aydin, M; Bayar, G; Kilinc, MF; Ofluoglu, Y; Yavuz, A	1
Baska, A; Gałązka, P; Leis, K; Mazur, E; Racinowski, M; Świerczyński, W	1
Chen, CH; Chuang, YC; Lee, WC; Shen, YC; Wang, HJ	1
Ikeuchi, T; Kikuchi, R; Okuyama, C	1
Athanasiou, S; Grigoriadis, T; Pitsouni, E; Salvatore, S; Serati, M; Zacharakis, D	1
Abdullatef, OA; Morshedy, S; Omar, M; Omran, G; Talaat, W	1
Berbée, JFP; Bilsen, MP; Boon, MR; Botani, K; Burakiewicz, J; Coskun, T; Dzyubachyk, O; Janssen, LGM; Jazet, IM; Kan, HE; Kooijman, S; Martinez-Tellez, B; Nahon, KJ; Overduin, LA; Rensen, PCN; Ruiz, JR; Sardjoe Mishre, ASD; van der Eijk, JA; van Dijk, KW; van Klinken, JB; van Weeghel, M; Vaz, FM; Webb, AG	1
Boucher, J; Harms, M; Maurer, S	1
Arlandis Guzmán, S; Blanco, N; Jiménez Cidre, MÁ; Landeira, M; Rubio-Rodríguez, D; Rubio-Terrés, C	1
Kwon, SY; Lee, KS; Park, DJ; Seo, YJ	1
Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A	1
Kato, D; Tabuchi, H; Takahashi, S; Uno, S	1
Burek, C; Corbetta, JP; Gomez, YR; Lopez Imizcoz, F; Ruiz, J; Sager, C; Sanmartino, M; Szklarz, T; Tessi, C; Vazquez Patiño, M; Weller, S	1
Bengtsson, T; Bokhari, MH; Chia, LY; Dehvari, N; Evans, BA; Gao, J; Ham, S; Hutchinson, DS; Kalinovich, A; Merlin, J; Mukaida, S; Nguyen, HTM; Sato, M; Summers, RJ; Whiting, L; Wootten, D	1
Brucker, BM; Charlson, ER; Enemchukwu, E; Howard, J; Jericevic, D; Krupp, L; Pape, D; Peyronnet, B; Rosenblum, N; Rude, T; Zhovtis-Ryerson, L	1
Hairston, J; Kraus, SR; Qian, C; Rogula, B; Shiozawa, A; Szabo, SM	1
El-Abd, AS; El-Abd, SA; Radwan, MH; Soliman, MG; Tawfik, AM	1
Chang, YS; Choo, MS; Kim, JC; Ko, KJ; Lee, KS	1
Araklitis, G; Cardozo, L; Robinson, D	1
Hairston, JC; Harrigan, S; Johnston, K; Kristy, RM; Lozano-Ortega, G; Mickle, A; Rogula, B; Schermer, CR; Walker, DR	1
Araklitis, G; Baines, G; Cardozo, L; da Silva, AS; Robinson, D	1
Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O	1
Ikeuchi, R; Koike, S; Okada, T; Soda, T; Tashiro, Y	1
Rechberger, T; Wróbel, A	1
Alves de Oliveira, H; Araújo de Oliveira, GL; Castano Silva, TB; da Silva Pereira, D; Zanghelini, F	1
Bonate, PL	1
Cambronero Santos, J; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT	1
Campeau, L; Fogaing, C; Mossa, AH	1
Berezina, TP; Evlakhov, VI; Poyassov, IZ	1
Bozkurt, O; Cinar, O; Cizmeci, S; Erbatu, O; Girgin, R; Irer, B; Kizilay, F; Ongun, S; Ozdemir, T; Ozer, S; Sen, V; Tanidir, Y; Ucer, O	1
Kakizaki, H; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O	1
Barnes, H; Bennett, AT; Brown, OE; Cardenas-Trowers, OO; Chang, OH; Escobar, C; Falk, KN; Hall, EF; Jeney, SES; Mehta, S; Menhaji, K; Ringel, NE; Sappenfield, EC; Tellechea, LM	1
Dellis, A; Fragkoulis, C; Gkialas, I; Glykas, I; Mitsikostas, DD; Mitsogiannis, I; Ntoumas, K; Papadopoulos, G; Papatsoris, A; Skolarikos, A	1
Cho, SY; Choo, MS; Jeong, SJ; Kim, J; Lee, S; Lee, SH; Oh, SJ	1
Sharma, G	1
Kumar, N; Prasad, V; Prashanth, YM; Saurav, K; Tyagi, V; Vasudeva, P; Yadav, S	1
Kaplan, SA; Mullen, GR	1
Bílková, K; Borovička, V; Cífková, R; Krhut, J; Kufová, E; Mokriš, J; Pudich, J; Sýkora, R; Wohlfahrt, P; Zachoval, R; Zvara, P	1
Waki, H; Yamauchi, T	1
Gambhire, M; Gambhire, V; Panchal, D; Raut, P	1
Selvi, I	1
Appenteng, K; Arana, A; Bahmanyar, S; de Vogel, S; Enger, C; Hallas, J; Hoffman, V; Horter, L; Kristiansen, NS; Linder, M; Margulis, A; Odsbu, I; Olesen, M; Perez-Gutthann, S; Phiri, K; Seeger, J; Suehs, B	1
Champilomatis, I; Dimitriadis, F; Filiponi, M; Kaltsas, A; Mamoulakis, C; Paliouras, A; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A	1
Bel, JS; Khaper, N; Lees, SJ; Tai, TC	1
Chimoto, J; Morikawa, K; Okura, T; Shiho, M; Shinozuka, K; Wakuda, H; Yamada, S	1
Aizawa, N; Fujimori, Y; Fujita, T; Goi, Y; Hayashi, T; Kobayashi, JI; Nakanishi, O	1
Behera, DP; Gupta, S; Singh, I; T K, A	1
Chae, C; Cheon, SH; Kim, SC; Kwon, T; Moon, KH; Park, M; Park, S; Yoon, JH	1
Ban, S; Iwahata, T; Kobori, Y; Okada, H; Osaka, A; Saito, K; Sato, Y; Sugimoto, K; Tanaka, T; Tokumoto, T	1
Hwang, YT; Kuo, HC; Lee, CL; Wang, CC	1
Carlson, KV; Deal, AS; Hairston, JC; Kristy, RM; Nair, KV; Rovner, ES	1
Abou-Ramadan, AR; El-Abd, AS; El-Abd, S; El-Gamal, OM; Raheem, AA; Soliman, MG	1
Mukai, S; Nomi, M; Sengoku, A; Yamada, S; Yanagiuchi, A	1
Furuhata, M; Hosaka, K; Ishizuka, O; Minagawa, T; Nakagawa, T; Ogawa, T; Saito, T; Suzuki, T	1
Keam, SJ	1
Baka-Ostrowska, M; Bolong, DT; Lademacher, C; Martin, N; Persu, C; Steup, A; Tøndel, C	1
Kellogg, D; Kelly, C; Koek, W; Kraus, S; Polk, M; Romo, T; Stowe, S; Trbovich, M	1
Fenner, A	1
Dang, HM; Jiang, HF; Liu, MR; Liu, XY; Wang, Y; Wu, XF; Xie, J; Yu, Y; Zhan, XJ; Zhang, HN	1
Burnett, AL; Karakus, S; Musicki, B	1
Appenteng, K; Arana, A; de Vogel, S; Enger, C; Hallas, J; Hoffman, V; Horter, L; Kristiansen, NS; Linder, M; Margulis, AV; Odsbu, I; Olesen, M; Perez-Gutthann, S; Phiri, K; Seeger, JD; Suehs, BT; Xu, Y	1
Aslan, F; Topcuoglu, M	1
Tang, QL; Tao, RZ; Wang, DJ; Zhou, S	1
Cheon, J; Kang, SG; Kang, SH; Lee, JG; Noh, TI; Shim, JS	1
Du, H; Hou, J; Li, N; Xu, F	1
Inoue, A; Kato, M; Kobayashi, K; Nagiri, C; Nishizawa, T; Nureki, O; Shihoya, W; Tomita, A; Yamashita, K	1
Chai, Y; Cui, Y; Li, Z; Zhang, Y	1
Cserni, BG; Cserni, G; Csont, T; Dinh, H; Farkas, K; Földesi, I; Freiwan, M; Horváth, P; Kovács, F; Kovács, MG; Kovács, ZZA; Kővári, B; Kriston, A; Márványkövi, FM; Sárközy, M; Siska, A; Szűcs, G	1
Ali, M; Choudhury, N; Covernton, PJO; Fatoye, F; Jaggi, A; Landeira, M; van Maanen, R	1
Byun, HJ; Cho, J; Foo, CY; Hadi, FA; Kang, D; Kim, S; Lee, KS; Park, H	1
Almgren-Rachtan, A; Chudek, J; Olszanecka-Glinianowicz, M; Owczarek, AJ; Zdrojowy, R	1
Chaudhry, N; Kumar, A; Kumar, N; Nagendra Rao, S; Patel, S; Prasad, V; Vasudeva, P; Yadav, P; Yadav, S	1
Girman, CJ; Kennelly, MJ; Mudd, PN; Rhodes, T; Shortino, D; Thomas, E	1
Ma, J; Sun, K; Wang, D; Wang, J; Wang, T; Wu, G; Wu, J	1
Ariman, A; Çulha, MG; Merder, E	1
Aitken, SJ; Ali, ZS; Billot, L; Bubb, KJ; Chow, C; Figtree, GA; Finemore, M; Golledge, J; Gray, MP; Grieve, SM; Hamburg, N; Harmer, JA; Keech, AC; Mister, R; Patel, S; Puttaswamy, V	1
Chandna, A; Devana, SK; Kumar, S; Mete, UK; Parmar, KM; Sharma, AP; Singh, SK	1
Yamanishi, T	1
Kuroishi, K; Mishima, Y; Takahashi, S; Ukai, M	1
Breinbjerg, A; Hagstrøm, S; Kamperis, K; Pedersen, N; Rittig, S; Thorsteinsson, K	1
Chakra, MA; Dabboucy, B; Dellis, A; Fares, Y; Moussa, M; Papatsoris, A	1
Claessens, M; De Coninck, V; Keller, EX; Merckx, L; Pietropaolo, A; Somani, B; Tailly, T; Van Besien, J	1
Yang, J; Yang, Y; Yi, W	1
Babu, R; Chadha, S; Chittibabu, T	1
Buyukokuroglu, ME; Kaya, RK; Mutlu, O; Ozturk, A; Tanyeri, MH; Tanyeri, P; Yavuz, K	1
Ferreira, GM; Fraga, R; Jaworski, P; Mello, GF; Oliveira, MH	1
De Coninck, V; Devos, B; Keller, EX	1
El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH	1
Matsuo, T; Miyata, Y; Sakai, H	1
Hennenberg, M; Huang, R; Stief, CG; Strittmatter, F; Tamalunas, A; Waidelich, R	1
Aldiss, P; Bloor, I; Boocock, DJ; Budge, H; Chavoshinejad, R; Ebling, FJP; Lewis, JE; Lupini, I; Miles, AK; Symonds, ME	1
Brychta, RJ; Chen, KY; Cypess, AM; Israni, NS; Jiang, A; Lea, HJ; Lentz, TN; Pierce, AE	1
Funahashi, Y	1
Raker, CA; Sripad, AA; Sung, VW	1
Cserni, G; Csont, T; Dinh, H; Dux, L; Földesi, I; Freiwan, M; Horváth, P; Kovács, F; Kovács, MG; Kovács, ZZA; Kriston, A; Losonczi, R; Sárközy, M; Siska, A; Szűcs, G	1
Bouhsina, N; Dagher, E; Desfontis, JC; Lalanne, V; Mallem, MY; Moughaizel, M; Thorin, C	1
Covernton, PJO; Martins de Almeida, R; Mateu Arrom, L; Mora Blazquez, AM; Ortíz Núñez, A	1
Ihara, T; Kira, S; Mitsui, T; Nakagomi, H; Sawada, N; Shimura, H; Takeda, M	1
Chen, Y; Dai, R; Deng, C	1
Boya, L; Chi, Z; Deyi, L; Liao, P; Yuanzhuo, C	1
Brubaker, L; Halverson, T; Mueller, ER; Wolfe, AJ	1
Chess-Williams, R; Lim, I	1
Chen, SF; Chuang, YC; Kuo, HC; Liao, CH; Wang, CC	1
An, J; Cho, HJ; Hur, KJ; Jang, JA; Kim, JS; Kim, YJ; Kwon, J; Lee, EJ; Park, D; Park, HR; Yang, H; Yoshimura, N	1
Ito, H; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K	1
Abdelaziz, AS; Ghoneem, AM; Salama, NM	1
Gundla, R; Konduru, N; Kowtharapu, LP	1
Gardner, I; Khoshaein, N; Kilford, P; Southall, R	1
Chess-Williams, R; McDermott, C; Sellers, DJ; West, EG	1
Cardillo, C; De Stefano, A; Di Daniele, N; Gentileschi, P; Schinzari, F; Sica, G; Tesauro, M; Vizioli, G	1
Hsiao, SM; Lin, HH; Su, TC; Tu, FC; Wu, PC	1
Akkoc, Y	1
Dmochowski, R; Gleicher, S; Reynolds, WS; Sebesta, EM	1
Fukuhara, H; Kinjo, M; Masuda, K; Miyakawa, J; Nakamura, Y; Tambo, M	1

Reviews

89 review(s) available for thiazoles and mirabegron

Article	Year
Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs : the investigational drugs journal, 2010, Volume: 13, Issue:10 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Rats; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urination Disorders	2010
Mirabegron: a safety review. Expert opinion on drug safety, 2011, Volume: 10, Issue:2 Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials, Phase II as Topic; Drug Interactions; Humans; Thiazoles; Urinary Bladder, Overactive	2011
Use of mirabegron in treating overactive bladder. International urogynecology journal, 2012, Volume: 23, Issue:10 Topics: Acetanilides; Adrenergic beta-Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2012
[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2012, Volume: 139, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials, Phase III as Topic; Humans; Muscle Relaxation; Muscle, Smooth; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive	2012
Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies. Postgraduate medicine, 2012, Volume: 124, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aniline Compounds; Behavior Therapy; Benzoates; Biphenyl Compounds; Botulinum Toxins, Type A; Clinical Trials as Topic; Electric Stimulation Therapy; Humans; Muscarinic Antagonists; Neuromuscular Agents; Sacrum; Thiazoles; Tibial Nerve; Urinary Bladder, Overactive	2012
Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management. Postgraduate medicine, 2012, Volume: 124, Issue:3 Topics: Acetanilides; Behavior Therapy; Botulinum Toxins, Type A; Catheter Ablation; Catheterization; Electric Stimulation Therapy; Exercise Therapy; Female; Humans; Neuromuscular Agents; Physical Therapy Modalities; Stem Cell Transplantation; Suburethral Slings; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urologic Surgical Procedures	2012
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:1 Topics: Acetanilides; Afferent Pathways; Animals; Botulinum Toxins, Type A; Carbolines; Humans; Phosphodiesterase 5 Inhibitors; Tadalafil; Thiazoles; Urinary Bladder, Overactive	2013
Selective β₃-adrenoceptor agonists for the treatment of overactive bladder. The Journal of urology, 2013, Volume: 190, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Urinary Bladder, Overactive	2013
Actual treatment of overactive bladder and urge urinary incontinence. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2013, Volume: 65, Issue:1 Topics: Acetanilides; Botulinum Toxins, Type A; Caffeine; Clinical Trials, Phase III as Topic; Drinking Behavior; Electric Stimulation Therapy; Electrodes, Implanted; Exercise Therapy; Female; Humans; Male; Multicenter Studies as Topic; Muscarinic Antagonists; Neurokinin-1 Receptor Antagonists; Pelvic Floor Disorders; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Therapies, Investigational; Thiazoles; Urinary Bladder Neck Obstruction; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urologic Surgical Procedures	2013
The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:5 Topics: Acetanilides; Biological Availability; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Europe; Humans; Japan; Kidney; Liver; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Thiazoles; United States; Urinary Bladder, Overactive	2013
β3-receptor agonists for overactive bladder--new frontier or more of the same? Current urology reports, 2013, Volume: 14, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Practice Guidelines as Topic; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urination	2013
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. International journal of clinical practice, 2013, Volume: 67, Issue:7 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult	2013
Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs, 2013, Volume: 73, Issue:11 Topics: Acetanilides; Humans; Randomized Controlled Trials as Topic; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2013
The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. International urology and nephrology, 2014, Volume: 46, Issue:1 Topics: Acetanilides; Clinical Trials, Phase III as Topic; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urination	2014
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? International urogynecology journal, 2014, Volume: 25, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Dose-Response Relationship, Drug; Female; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2014
Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy. Urology journal, 2013, Sep-26, Volume: 10, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2013
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourology and urodynamics, 2014, Volume: 33, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2014
[Drug therapy of bladder dysfunction]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15 Topics: Acetanilides; Anti-Inflammatory Agents; Botulinum Toxins, Type A; Cholinergic Antagonists; Cimetidine; Cyclosporine; Dimethyl Sulfoxide; Histamine H2 Antagonists; Humans; Immunosuppressive Agents; Muscarinic Antagonists; Neuromuscular Agents; Phosphodiesterase Inhibitors; Thiazoles; Urinary Bladder; Urinary Bladder Diseases; Urination; Urodynamics	2013
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. European urology, 2014, Volume: 65, Issue:4 Topics: Acetanilides; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2014
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World journal of urology, 2014, Volume: 32, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Young Adult	2014
Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert opinion on drug discovery, 2014, Volume: 9, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urinary Tract; Urological Agents	2014
Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). BJU international, 2015, Volume: 115, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2015
The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age and ageing, 2014, Volume: 43, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Clinical Trials, Phase III as Topic; Humans; Randomized Controlled Trials as Topic; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2014
Mirabegron in the treatment of overactive bladder. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:6 Topics: Acetanilides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2014
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist]. Ginekologia polska, 2014, Volume: 85, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence	2014
Cost-effectiveness of novel therapies for overactive bladder. Expert review of pharmacoeconomics & outcomes research, 2014, Volume: 14, Issue:4 Topics: Acetanilides; Adult; Behavior Therapy; Botulinum Toxins, Type A; Cost-Benefit Analysis; Electric Stimulation Therapy; Humans; Muscarinic Antagonists; Thiazoles; Tibial Nerve; Urinary Bladder, Overactive	2014
The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urologia internationalis, 2014, Volume: 93, Issue:3 Topics: Acetanilides; Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Odds Ratio; Phenylpropanolamine; Prospective Studies; Research Design; Software; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2014
Neurogenic bladder: from diagnosis to management. Current urology reports, 2014, Volume: 15, Issue:10 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Botulinum Toxins, Type A; Catheters, Indwelling; Humans; Muscarinic Antagonists; Neuromuscular Agents; Plastic Surgery Procedures; Spinal Cord Injuries; Thiazoles; Urethra; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Catheterization; Urinary Diversion; Urodynamics	2014
The use of pharmacotherapy for male patients with urgency and stress incontinence. Current opinion in urology, 2014, Volume: 24, Issue:6 Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urinary Incontinence, Urge; Urological Agents	2014
Mirabegron: a Beta-3 agonist for overactive bladder. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2014, Volume: 29, Issue:12 Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2014
[Urinary incontinence: what's new in therapy?]. Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:3 Topics: Acetanilides; Administration, Intravesical; Aged; Behavior Therapy; Botulinum Toxins, Type A; Cholinergic Antagonists; Combined Modality Therapy; Cooperative Behavior; Female; Humans; Interdisciplinary Communication; Male; Thiazoles; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence	2015
Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects. Drugs, 2015, Volume: 75, Issue:15 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2015
Emerging drugs for overactive bladder. Expert opinion on emerging drugs, 2015, Volume: 20, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Botulinum Toxins, Type A; Drug Design; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Quality of Life; Thiazoles; Urinary Bladder, Overactive	2015
Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. European urology, 2016, Volume: 69, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aniline Compounds; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Heart Rate; Humans; Thiazoles; Urinary Bladder, Overactive	2016
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Current medical research and opinion, 2016, Volume: 32, Issue:4 Topics: Acetanilides; Administration, Oral; Adrenergic beta-Antagonists; Aged; Benzhydryl Compounds; Blood Pressure; Clinical Trials as Topic; Constipation; Female; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Retrospective Studies; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive	2016
Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison. BMJ open, 2016, Feb-23, Volume: 6, Issue:2 Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Nocturia; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2016
Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies. Expert opinion on drug safety, 2016, Volume: 15, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aniline Compounds; Animals; Benzoates; Biphenyl Compounds; Gene Expression Profiling; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive	2016
A drug safety evaluation of mirabegron in the management of overactive bladder. Expert opinion on drug safety, 2016, Volume: 15, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2016
Cardiac salvage by tweaking with beta-3-adrenergic receptors. Cardiovascular research, 2016, 07-15, Volume: 111, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Endothelial Cells; Heart Diseases; Humans; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Receptors, Adrenergic, beta-3; Signal Transduction; Thiazoles; Ventricular Remodeling	2016
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:2 Topics: Acetanilides; Aged; Asia; Humans; Male; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
New and Emerging Therapies and Targets: Beta-3 Agonists. Handbook of experimental pharmacology, 2017, Volume: 243 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Catecholamines; Heart Failure; Humans; Myocytes, Cardiac; Nitric Oxide; Receptors, Adrenergic, beta-3; Signal Transduction; Thiazoles; Ventricular Remodeling	2017
β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview. Current drug targets, 2018, Volume: 19, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Lower Urinary Tract Symptoms; Male; Male Urogenital Diseases; Muscarinic Antagonists; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive	2018
[Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2017, Volume: 27, Issue:4 Topics: Acetanilides; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2017
Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug design, development and therapy, 2017, Volume: 11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Urinary Bladder, Overactive	2017
Current evidence and emerging drug therapies for overactive bladder. Minerva ginecologica, 2017, Volume: 69, Issue:3 Topics: Acetanilides; Drug Design; Humans; Muscarinic Antagonists; Quality of Life; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
[Comprehensive pharmacologic management of overactive bladder]. Urologiia (Moscow, Russia : 1999), 2017, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Combinations; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive	2017
[Mirabegron, a breakthrough in overactive bladder syndrome?] Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2017, May-01, Volume: 41, Issue:3 Topics: Acetanilides; Humans; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2017
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU international, 2017, Volume: 120, Issue:5 Topics: Acetanilides; Administration, Oral; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2017
Safety issues associated with using medication to treat overactive bladder. Expert opinion on drug safety, 2017, Volume: 16, Issue:11 Topics: Acetanilides; Aged; Botulinum Toxins; Cholinergic Antagonists; Estrogens; Humans; Polypharmacy; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:3 Topics: Acetanilides; Humans; Lower Urinary Tract Symptoms; Nocturia; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Mirabegron: potential off target effects and uses beyond the bladder. British journal of pharmacology, 2018, Volume: 175, Issue:21 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder	2018
[The place of mirabegron in clinical practice]. Urologiia (Moscow, Russia : 1999), 2017, Issue:6 Topics: Acetanilides; Female; Humans; Male; Thiazoles; Urinary Bladder, Neurogenic; Urinary Incontinence	2017
Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. Expert opinion on drug safety, 2018, Volume: 17, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cardiovascular Diseases; Heart Rate; Humans; Hypertension; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2018
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. World journal of urology, 2018, Volume: 36, Issue:8 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents	2018
Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand? European urology focus, 2019, Volume: 5, Issue:6 Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Aged; Case-Control Studies; Cholinergic Antagonists; Drug Therapy, Combination; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Compliance; Prevalence; Quality of Life; Thiazoles; Urinary Bladder, Overactive	2019
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. European urology, 2018, Volume: 74, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Recovery of Function; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2018
Mirabegron: A Review in Overactive Bladder Syndrome. Drugs, 2018, Volume: 78, Issue:8 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Muscarinic Antagonists; Signal Transduction; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2018
Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourology and urodynamics, 2019, Volume: 38, Issue:1 Topics: Acetanilides; Humans; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2019
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ open, 2018, 11-21, Volume: 8, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Medication Adherence; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2018
[Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder.] Archivos espanoles de urologia, 2018, Volume: 71, Issue:10 Topics: Acetanilides; Cost-Benefit Analysis; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2018
[New approach to the treatment of patients with overactive bladder. Mirabegron: past, present and future]. Urologiia (Moscow, Russia : 1999), 2018, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Russia; Thiazoles; Urinary Bladder, Overactive	2018
Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review. Advances in therapy, 2019, Volume: 36, Issue:3 Topics: Acetanilides; Botulinum Toxins, Type A; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2019
The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. Urology, 2019, Volume: 127 Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Antagonists; Aged; Aged, 80 and over; Bayes Theorem; Botulinum Toxins, Type A; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Muscarinic Antagonists; Network Meta-Analysis; Prognosis; Randomized Controlled Trials as Topic; Retreatment; Thiazoles; Treatment Failure; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics	2019
Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study. Journal of pediatric surgery, 2020, Volume: 55, Issue:2 Topics: Acetanilides; Adolescent; Child; Female; Humans; Male; Pilot Projects; Retrospective Studies; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2020
The use of mirabegron in neurogenic bladder: a systematic review. World journal of urology, 2020, Volume: 38, Issue:10 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic	2020
The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Medicine, 2020, Volume: 99, Issue:4 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
What affects the placebo effect? European journal of obstetrics, gynecology, and reproductive biology, 2020, Volume: 246 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Data Collection; Humans; Patient Reported Outcome Measures; Placebo Effect; Thiazoles; Urinary Bladder, Overactive	2020
Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome. Current drug metabolism, 2020, Volume: 21, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Delayed-Action Preparations; Humans; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2020
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient. Clinical interventions in aging, 2020, Volume: 15 Topics: Acetanilides; Age Factors; Aged; Aged, 80 and over; Female; Humans; Lower Urinary Tract Symptoms; Nocturia; Patient Safety; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2020
Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019. Current opinion in urology, 2020, Volume: 30, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Botulinum Toxins, Type A; Humans; Lower Urinary Tract Symptoms; Muscarinic Antagonists; Nocturia; Thiazoles; Urinary Bladder, Neurogenic; Urological Agents	2020
Effect of Mirabegron on the Body's Exercise Capacity: A Review. Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:9 Topics: Acetanilides; Adipose Tissue; Adipose Tissue, Brown; Adipose Tissue, White; Adrenergic beta-3 Receptor Agonists; Animals; Exercise Tolerance; Humans; Lipolysis; Thiazoles; Urinary Bladder, Overactive	2020
Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis. European journal of obstetrics, gynecology, and reproductive biology, 2020, Volume: 251 Topics: Acetanilides; Female; Humans; Male; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
The colorful versatility of adipocytes: white-to-brown transdifferentiation and its therapeutic potential in humans. The FEBS journal, 2021, Volume: 288, Issue:12 Topics: Acetanilides; Adipocytes, Beige; Adipocytes, Brown; Adipocytes, White; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Lineage; Cell Transdifferentiation; Diabetes Mellitus; Drugs, Investigational; Energy Metabolism; Humans; Imatinib Mesylate; Obesity; Roscovitine; Thermogenesis; Thiazoles	2021
Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. Clinical interventions in aging, 2020, Volume: 15 Topics: Acetanilides; Aged; Behavior Therapy; Benzilates; Blood-Brain Barrier; Cholinergic Antagonists; Cognitive Dysfunction; Female; Humans; Muscarinic Antagonists; Nortropanes; Thiazoles; Urinary Bladder, Overactive	2020
Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis. Drugs & aging, 2020, Volume: 37, Issue:11 Topics: Acetanilides; Aged; Benzhydryl Compounds; Constipation; Female; Humans; Male; Muscarinic Antagonists; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
Recent advances in managing overactive bladder. F1000Research, 2020, Volume: 9 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Botulinum Toxins; Denervation; Drug Implants; Humans; Laser Therapy; Pyrimidinones; Pyrrolidines; Tamoxifen; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
Evaluating vibegron for the treatment of overactive bladder. Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder? Current urology reports, 2020, Oct-22, Volume: 21, Issue:12 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Cost-Benefit Analysis; Humans; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Pyrimidinones; Pyrrolidines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. Current urology reports, 2021, Jan-07, Volume: 22, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Mirabegron: The most promising adipose tissue beiging agent. Physiological reports, 2021, Volume: 9, Issue:5 Topics: Acetanilides; Adipose Tissue; Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Energy Metabolism; Humans; Obesity; Thiazoles	2021
Mirabegron: Pediatric First Approval. Paediatric drugs, 2021, Volume: 23, Issue:4 Topics: Acetanilides; Administration, Oral; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Male; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2021, Volume: 31, Issue:11 Topics: Acetanilides; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Aktuelle Urologie, 2021, Volume: 52, Issue:4 Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Neurogenic	2021
The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: A systematic review and meta-analysis. Lower urinary tract symptoms, 2022, Volume: 14, Issue:1 Topics: Acetanilides; Humans; Male; Stents; Thiazoles; Treatment Outcome; Ureter	2022
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison. Advances in therapy, 2021, Volume: 38, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis. European urology focus, 2022, Volume: 8, Issue:4 Topics: Acetanilides; Adult; Humans; Male; Pain; Quality of Life; Thiazoles; Ureter	2022
Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis. Medicine, 2021, Oct-15, Volume: 100, Issue:41 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cholinergic Antagonists; Constipation; Female; Humans; Hypertension; Male; Middle Aged; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Safety; Tachycardia; Thiazoles; Urinary Bladder, Overactive; Urinary Tract Infections; Vision, Low; Xerostomia	2021
The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis. Neurourology and urodynamics, 2022, Volume: 41, Issue:5 Topics: Acetanilides; Adult; Child; Humans; Prospective Studies; Quality of Life; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder	2022
Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review. Spinal cord, 2022, Volume: 60, Issue:10 Topics: Acetanilides; Adult; Cholinergic Antagonists; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; Retrospective Studies; Spinal Cord Injuries; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics	2022

Trials

119 trial(s) available for thiazoles and mirabegron

Article	Year
Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:4 Topics: Absorption; Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Adult; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Humans; Male; Mass Spectrometry; Metabolic Clearance Rate; Molecular Structure; Receptors, Adrenergic, beta-3; Thiazoles; Young Adult	2012
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:11 Topics: Acetanilides; Administration, Oral; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Biotransformation; Body Weight; Cross-Over Studies; Female; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Netherlands; Sex Factors; Thiazoles; Urinary Bladder, Overactive; Washington; Young Adult	2012
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clinical therapeutics, 2012, Volume: 34, Issue:10 Topics: Acetanilides; Administration, Oral; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Sex Factors; Tandem Mass Spectrometry; Thiazoles; Time Factors; Young Adult	2012
Results of a randomized phase III trial of mirabegron in patients with overactive bladder. The Journal of urology, 2013, Volume: 189, Issue:4 Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive	2013
Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:6 Topics: Acetanilides; Adolescent; Adrenergic beta-Agonists; Adult; Anti-Infective Agents; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Sex Characteristics; Thiazoles; Urinary Bladder, Overactive; Young Adult	2012
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. European urology, 2013, Volume: 63, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Australia; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Single-Blind Method; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination	2013
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. European urology, 2013, Volume: 63, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Headache; Humans; Hypertension; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Single-Blind Method; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urinary Retention; Xerostomia	2013
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clinical drug investigation, 2013, Volume: 33, Issue:1 Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Kidney; Kidney Diseases; Liver; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Severity of Illness Index; Thiazoles	2013
β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. International urology and nephrology, 2013, Volume: 45, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Thiazoles; Ultrasonography; Urinary Bladder, Overactive; Urodynamics	2013
A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourology and urodynamics, 2013, Volume: 32, Issue:8 Topics: Acetanilides; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Nocturia; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents	2013
A phase II dose-ranging study of mirabegron in patients with overactive bladder. International urogynecology journal, 2013, Volume: 24, Issue:9 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Internationality; Male; Middle Aged; Quality of Life; Single-Blind Method; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2013
Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Clinical therapeutics, 2013, Volume: 35, Issue:3 Topics: Acetanilides; Administration, Oral; Adrenergic beta-Agonists; Adult; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Male; Reference Values; Thiazoles	2013
Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013, Volume: 29, Issue:7 Topics: Acetanilides; Adolescent; Adult; Aged; Double-Blind Method; Eye; Female; Healthy Volunteers; Humans; Intraocular Pressure; Male; Middle Aged; Thiazoles; Tissue Distribution; Treatment Outcome; Visual Acuity; Young Adult	2013
Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clinical drug investigation, 2013, Volume: 33, Issue:6 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Interactions; Female; Half-Life; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Thiazoles; Young Adult	2013
Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. The Journal of urology, 2013, Volume: 190, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Thiazoles; Urinary Bladder Neck Obstruction; Urodynamics	2013
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Thiazoles; Urinary Bladder, Overactive; Young Adult	2014
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology, 2013, Volume: 82, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Female; Headache; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tachycardia; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Urge	2013
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC urology, 2013, Sep-18, Volume: 13 Topics: Acetanilides; Aged; Aged, 80 and over; Australia; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prevalence; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2013
Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Clinical drug investigation, 2014, Volume: 34, Issue:1 Topics: Acetanilides; Adrenergic Agonists; Adult; Asian People; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Japan; Male; Single-Blind Method; Thiazoles; Urinary Bladder, Overactive; Young Adult	2014
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU international, 2014, Volume: 113, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Asian People; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive	2014
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). European urology, 2015, Volume: 67, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents	2015
Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. International journal of clinical practice, 2014, Volume: 68, Issue:8 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Off-Label Use; Placebos; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2014
Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men. International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:8 Topics: Acetanilides; Adult; Aged; Area Under Curve; Blood Pressure; Cross-Over Studies; Drug Interactions; Exercise Test; Half-Life; Heart Rate; Humans; Male; Middle Aged; Sulfonamides; Tamsulosin; Thiazoles; Urological Agents	2014
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:10 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Headache; Humans; Hypertension; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention; Urinary Tract Infections; Urination; Xerostomia	2014
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. European urology, 2015, Volume: 67, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination	2015
Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and urodynamics, 2015, Volume: 34, Issue:7 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Asia; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Recovery of Function; Surveys and Questionnaires; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents	2015
A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. The Journal of urology, 2015, Volume: 193, Issue:3 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Overactive	2015
Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clinical drug investigation, 2015, Volume: 35, Issue:2 Topics: Acetanilides; Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Double-Blind Method; Humans; Phenylpropanolamine; Quality of Life; Thiazoles; Tolterodine Tartrate; United Kingdom; Urinary Bladder, Overactive; Urological Agents	2015
Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell metabolism, 2015, Jan-06, Volume: 21, Issue:1 Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic Agonists; Basal Metabolism; Chromatography, High Pressure Liquid; Fluorodeoxyglucose F18; Glucose; Humans; Male; Obesity; Positron-Emission Tomography; Receptors, Adrenergic, beta-3; Tandem Mass Spectrometry; Thiazoles; Tomography, X-Ray Computed; Young Adult	2015
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU international, 2015, Volume: 116, Issue:4 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2015
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:7 Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2015
Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology, 2015, Volume: 85, Issue:4 Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Prospective Studies; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents	2015
Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Clinical therapeutics, 2015, May-01, Volume: 37, Issue:5 Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Asian People; Eating; Fasting; Female; Healthy Volunteers; Humans; Male; Sex Factors; Thiazoles; Urinary Bladder, Overactive; Urological Agents; Young Adult	2015
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB. Neurourology and urodynamics, 2016, Volume: 35, Issue:6 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2016
Patient-reported outcomes with the β Neurourology and urodynamics, 2016, Volume: 35, Issue:8 Topics: Absenteeism; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Incontinence Pads; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Quality of Life; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive	2016
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder. Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Decision Support Techniques; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Risk Assessment; Risk Factors; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2016
Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. Lower urinary tract symptoms, 2015, Volume: 7, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2015
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European urology, 2016, Volume: 70, Issue:1 Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2016
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected]. The Journal of urology, 2016, Volume: 196, Issue:3 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics; Young Adult	2016
Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Urologia internationalis, 2016, Volume: 97, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics	2016
Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study). Actas urologicas espanolas, 2016, Volume: 40, Issue:9 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2016
Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). Neurourology and urodynamics, 2017, Volume: 36, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Imidazoles; Middle Aged; Muscarinic Antagonists; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2017
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYM World journal of urology, 2017, Volume: 35, Issue:5 Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2017
Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study. International journal of urology : official journal of the Japanese Urological Association, 2016, Volume: 23, Issue:12 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cardiovascular Diseases; Female; Humans; Male; Marketing; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2016
Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). International journal of urology : official journal of the Japanese Urological Association, 2016, Volume: 23, Issue:12 Topics: Acetanilides; Double-Blind Method; Female; Humans; Imidazoles; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2016
Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. Lower urinary tract symptoms, 2018, Volume: 10, Issue:2 Topics: Acetanilides; Drug Substitution; Female; Humans; Long-Term Care; Postmenopause; Prospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. European journal of heart failure, 2017, Volume: 19, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Thiazoles; Tomography, X-Ray Computed	2017
Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β Lower urinary tract symptoms, 2017, Volume: 9, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult	2017
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU international, 2017, Volume: 120, Issue:4 Topics: Acetanilides; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Internationality; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Risk Assessment; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2017
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). International journal of clinical practice, 2017, Volume: 71, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2017
Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study. Lower urinary tract symptoms, 2018, Volume: 10, Issue:3 Topics: Acetanilides; Adult; Female; Humans; Middle Aged; Prospective Studies; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination; Urine; Urodynamics; Urological Agents	2018
An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects. Journal of clinical pharmacology, 2017, Volume: 57, Issue:12 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Bisoprolol; Cardiac Output; Cross-Over Studies; Humans; Male; Propranolol; Renin; Stroke Volume; Thiazoles; Young Adult	2017
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). International urogynecology journal, 2018, Volume: 29, Issue:2 Topics: Acetanilides; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Preference; Prospective Studies; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. The patient, 2017, Volume: 10, Issue:6 Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and urodynamics, 2018, Volume: 37, Issue:1 Topics: Acetanilides; Double-Blind Method; Drug Therapy, Combination; Humans; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Visual Analog Scale	2018
Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study. Lower urinary tract symptoms, 2019, Volume: 11, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Product Surveillance, Postmarketing; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2019
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. European urology focus, 2017, Volume: 3, Issue:6 Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2017
Is it possible to cure the symptoms of the overactive bladder in women? International urology and nephrology, 2018, Volume: 50, Issue:3 Topics: Acetanilides; Aged; Feasibility Studies; Female; Humans; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Recurrence; Severity of Illness Index; Symptom Assessment; Thiazoles; Time Factors; Urinary Bladder, Overactive; Urological Agents; Withholding Treatment	2018
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood pressure monitoring, 2018, Volume: 23, Issue:3 Topics: Acetanilides; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles	2018
Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourology and urodynamics, 2018, Volume: 37, Issue:7 Topics: Acetanilides; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents; Young Adult	2018
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health and quality of life outcomes, 2018, Apr-19, Volume: 16, Issue:1 Topics: Acetanilides; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Quality of Life; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents	2018
Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. BJU international, 2018, Volume: 122, Issue:5 Topics: Acetanilides; Adult; Aged; Female; Humans; Male; Middle Aged; Pain, Postoperative; Prospective Studies; Stents; Thiazoles; Treatment Outcome; Ureter; Ureteral Calculi; Urological Agents	2018
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). European urology, 2018, Volume: 74, Issue:4 Topics: Acetanilides; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Symptom Assessment; Thiazoles; Time; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Be ESC heart failure, 2018, Volume: 5, Issue:5 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Diastole; Disease Progression; Double-Blind Method; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Prospective Studies; Stroke Volume; Thiazoles; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling; Young Adult	2018
The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC urology, 2018, Jun-25, Volume: 18, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Humans; Middle Aged; Orgasm; Prospective Studies; Sexual Health; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Human adipose beiging in response to cold and mirabegron. JCI insight, 2018, 08-09, Volume: 3, Issue:15 Topics: Acetanilides; Adipose Tissue, Beige; Adrenergic beta-3 Receptor Agonists; Adult; Biopsy; Cold Temperature; Energy Metabolism; Female; Humans; Lipid Metabolism; Male; Membrane Proteins; Middle Aged; Obesity; Subcutaneous Fat; Thermogenesis; Thiazoles; Uncoupling Protein 1	2018
A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourology and urodynamics, 2018, Volume: 37, Issue:8 Topics: Acetanilides; Adult; Aged; Canada; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pilot Projects; Spinal Cord Injuries; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics	2018
Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder. Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:3 Topics: Acetanilides; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Taiwan; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2019
Acute metabolic and cardiovascular effects of mirabegron in healthy individuals. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:2 Topics: Acetanilides; Adipose Tissue, Brown; Adolescent; Adult; Blood Pressure; Cardiovascular System; Dose-Response Relationship, Drug; Drug Administration Schedule; Energy Metabolism; Female; Healthy Volunteers; Heart Rate; Humans; Male; Pilot Projects; Skin Temperature; Thermogenesis; Thiazoles; Young Adult	2019
Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Neurourology and urodynamics, 2019, Volume: 38, Issue:1 Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents	2019
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood Pressure; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Nasopharyngitis; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia	2019
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourology and urodynamics, 2019, Volume: 38, Issue:2 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult	2019
Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies. Neurourology and urodynamics, 2019, Volume: 38, Issue:3 Topics: Acetanilides; Aged; Aged, 80 and over; Benzhydryl Compounds; Drug Therapy, Combination; Humans; Indoles; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2019
Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling? BioMed research international, 2019, Volume: 2019 Topics: Acetanilides; Adult; Aged; Female; Humans; Lower Urinary Tract Symptoms; Middle Aged; Prospective Studies; Solifenacin Succinate; Suburethral Slings; Thiazoles	2019
Adjunction of tamsulosin or mirabegron before semi-rigid ureterolithotripsy improves outcomes: prospective, randomized single-blind study. International urology and nephrology, 2019, Volume: 51, Issue:6 Topics: Acetanilides; Adult; Combined Modality Therapy; Female; Humans; Lithotripsy; Male; Prospective Studies; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Ureteral Calculi; Ureteroscopy; Urological Agents	2019
Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms. International journal of urology : official journal of the Japanese Urological Association, 2020, Volume: 27, Issue:1 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Lower urinary tract symptoms, 2020, Volume: 12, Issue:1 Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. European urology, 2020, Volume: 77, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Databases, Factual; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive	2020
Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study. Acta medica Okayama, 2019, Volume: 73, Issue:5 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Middle Aged; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Visual Analog Scale	2019
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). European urology focus, 2020, 07-15, Volume: 6, Issue:4 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). European urology, 2020, Volume: 77, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Male; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study. International urology and nephrology, 2020, Volume: 52, Issue:5 Topics: Acetanilides; Adult; Female; Humans; Indoles; Male; Middle Aged; Prospective Studies; Thiazoles; Treatment Outcome; Ureteral Calculi	2020
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). The Journal of urology, 2020, Volume: 203, Issue:6 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial. Archivos espanoles de urologia, 2020, Volume: 73, Issue:1 Topics: Acetanilides; Adult; Drug Therapy, Combination; Humans; Middle Aged; Quality of Life; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Catheters; Urological Agents	2020
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. The Journal of clinical investigation, 2020, 05-01, Volume: 130, Issue:5 Topics: Acetanilides; Adipose Tissue, Brown; Adolescent; Adult; Apolipoprotein A-I; Biomarkers; Cholesterol, HDL; Female; Humans; Insulin Resistance; Positron Emission Tomography Computed Tomography; Thiazoles; Urinary Bladder, Overactive	2020
The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. The Journal of clinical investigation, 2020, 05-01, Volume: 130, Issue:5 Topics: Acetanilides; Adipocytes; Adipose Tissue, Beige; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Biopsy; Blood Glucose; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Muscle, Skeletal; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Thiazoles	2020
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourology and urodynamics, 2020, Volume: 39, Issue:2 Topics: Acetanilides; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2020
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC geriatrics, 2020, 03-18, Volume: 20, Issue:1 Topics: Acetanilides; Aged; Cognition; Female; Humans; Male; Mental Status and Dementia Tests; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study. Lower urinary tract symptoms, 2021, Volume: 13, Issue:1 Topics: Acetanilides; Adult; Female; Humans; Lithotripsy; Lower Urinary Tract Symptoms; Male; Middle Aged; Stents; Surveys and Questionnaires; Tamsulosin; Thiazoles; Ureter; Urological Agents	2021
The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:11 Topics: Acetanilides; Adipose Tissue, Brown; Asian People; Cold Temperature; Cross-Over Studies; Energy Metabolism; Humans; Male; Thermogenesis; Thiazoles	2020
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet. Drugs & aging, 2020, Volume: 37, Issue:9 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2020
Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study. Urology, 2020, Volume: 145 Topics: Acetanilides; Adult; Constipation; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Patient Reported Outcome Measures; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World journal of urology, 2021, Volume: 39, Issue:6 Topics: Acetanilides; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Single-Blind Method; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Lower urinary tract symptoms, 2021, Volume: 13, Issue:1 Topics: Acetanilides; Age Factors; Aged; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Tamsulosin; Thiazoles; Urinary Bladder, Overactive	2021
Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study. Urology, 2021, Volume: 147 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Urinary Bladder, Overactive	2021
Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study. Advances in therapy, 2021, Volume: 38, Issue:1 Topics: Acetanilides; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Quality of Life; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study. World journal of urology, 2021, Volume: 39, Issue:8 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Drug Monitoring; Female; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Multiple Sclerosis; Single-Blind Method; Symptom Assessment; Thiazoles; Treatment Outcome; Ultrasonography	2021
Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourology and urodynamics, 2021, Volume: 40, Issue:1 Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity. International urology and nephrology, 2021, Volume: 53, Issue:6 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Spinal Cord Injuries; Thiazoles; Urinary Bladder, Overactive; Young Adult	2021
Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud International journal of clinical practice, 2021, Volume: 75, Issue:7 Topics: Acetanilides; Drug Therapy, Combination; Humans; Male; Prostatic Hyperplasia; Quality of Life; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. Lower urinary tract symptoms, 2021, Volume: 13, Issue:4 Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial. Urologia internationalis, 2021, Volume: 105, Issue:11-12 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Age Factors; Child; Child, Preschool; Egypt; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2021
Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:9 Topics: Acetanilides; Double-Blind Method; Female; Humans; Mandelic Acids; Nocturia; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study. World journal of urology, 2021, Volume: 39, Issue:12 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Prospective Studies; Thiazoles; Treatment Outcome; Ureteral Calculi	2021
Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study. Neurourology and urodynamics, 2021, Volume: 40, Issue:8 Topics: Acetanilides; Adult; Benzofurans; Humans; Prospective Studies; Pyrrolidines; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. Cancer medicine, 2021, Volume: 10, Issue:21 Topics: Acetanilides; Aged; BCG Vaccine; Cystectomy; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Thiazoles; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urological Agents	2021
Protocol for the Stimulating β BMJ open, 2021, 09-28, Volume: 11, Issue:9 Topics: Acetanilides; Clinical Trials, Phase II as Topic; Double-Blind Method; Humans; Multicenter Studies as Topic; Peripheral Arterial Disease; Physical Functional Performance; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Adrenergic, beta-3; Thiazoles; Walking	2021
Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial. Urologia, 2022, Volume: 89, Issue:4 Topics: Acetanilides; Humans; Pain; Prospective Studies; Quality of Life; Solifenacin Succinate; Stents; Tamsulosin; Thiazoles; Treatment Outcome; Urological Agents	2022
Efficacy of mirabegron, a β International journal of urology : official journal of the Japanese Urological Association, 2022, Volume: 29, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Female; Humans; Japan; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2022
The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. Scandinavian journal of urology, 2022, Volume: 56, Issue:1 Topics: Acetanilides; Double-Blind Method; Humans; Parkinson Disease; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2022
Mirabegron as effective as oxybutynin for ureteral stent symptoms. Revista da Associacao Medica Brasileira (1992), 2021, Volume: 67, Issue:12 Topics: Acetanilides; Humans; Mandelic Acids; Prospective Studies; Quality of Life; Stents; Surveys and Questionnaires; Thiazoles	2021
RE: mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study. World journal of urology, 2022, Volume: 40, Issue:5 Topics: Acetanilides; Female; Humans; Male; Prospective Studies; Thiazoles; Treatment Outcome; Ureteral Calculi	2022
Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. International journal of urology : official journal of the Japanese Urological Association, 2022, Volume: 29, Issue:5 Topics: Acetanilides; Doxazosin; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Thiazoles; Tolterodine Tartrate; Treatment Outcome	2022
Editorial Comment from Dr Matsuo et al. to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. International journal of urology : official journal of the Japanese Urological Association, 2022, Volume: 29, Issue:5 Topics: Acetanilides; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Diseases; Thiazoles	2022
Editorial Comment from Dr Funahashi to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. International journal of urology : official journal of the Japanese Urological Association, 2022, Volume: 29, Issue:5 Topics: Acetanilides; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Diseases; Thiazoles	2022
Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study. Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:10 Topics: Acetanilides; Aged; Aged, 80 and over; Central Nervous System Diseases; Cognition; Cohort Studies; Drug Therapy, Combination; Humans; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2022
Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms. World journal of urology, 2022, Volume: 40, Issue:8 Topics: Acetanilides; Humans; Quality of Life; Solifenacin Succinate; Stents; Thiazoles; Treatment Outcome; Urological Agents	2022
Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial. Scientific reports, 2022, 08-20, Volume: 12, Issue:1 Topics: Acetanilides; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Vascular Stiffness	2022
Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study. Urology, 2023, Volume: 175 Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Prospective Studies; Pyrimidinones; Pyrrolidines; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2023

Other Studies

289 other study(ies) available for thiazoles and mirabegron

Article	Year
Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Animals; Carbachol; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Humans; Isoproterenol; Muscle Contraction; Propanolamines; Thiazoles; Urinary Bladder	2007
Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. European urology, 2009, Volume: 56, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Aprepitant; Female; Humans; Morpholines; Pyrazoles; Receptors, Neurokinin-1; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics	2009
Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors? British journal of pharmacology, 2009, Volume: 156, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Binding, Competitive; Biphenyl Compounds; Cell Line; Cyclic AMP; Humans; Isoproterenol; Mutagenesis, Site-Directed; Norepinephrine; Phenethylamines; Polymorphism, Single Nucleotide; Propanolamines; Radioligand Assay; Receptors, Adrenergic, beta-3; Thiazoles; Transfection	2009
Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Mar-01, Volume: 887-888 Topics: Acetanilides; Chromatography, High Pressure Liquid; Drug Stability; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles	2012
Mirabegron for the treatment of overactive bladder. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Interactions; Humans; Thiazoles; Urinary Bladder, Overactive	2012
An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2012, Aug-15, Volume: 46, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aniline Compounds; Benzoates; Biphenyl Compounds; Carbachol; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Ligands; Male; Muscle Relaxation; Muscle, Smooth; Propanolamines; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder	2012
Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica; the fate of foreign compounds in biological systems, 2012, Volume: 42, Issue:10 Topics: Acetanilides; Acetylcholinesterase; Adrenergic beta-3 Receptor Agonists; Antibodies, Monoclonal; Butyrylcholinesterase; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Esterases; Female; Humans; Hydrolysis; Immune Sera; Isoenzymes; Kinetics; Liver; Male; Microsomes, Liver; Oxygenases; Receptors, Adrenergic, beta-3; Recombinant Proteins; Solutions; Thiazoles	2012
Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU international, 2012, Volume: 110, Issue:2 Pt 2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Infusions, Intravenous; Muscarinic Antagonists; Phenylpropanolamine; Rats; Rats, Sprague-Dawley; Thiazoles; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urination	2012
Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU international, 2012, Volume: 110, Issue:2 Pt 2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Female; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urination	2012
In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica; the fate of foreign compounds in biological systems, 2012, Volume: 42, Issue:12 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hepatocytes; High-Throughput Screening Assays; Humans; Male; Microsomes, Liver; Middle Aged; NADP; Recombinant Proteins; RNA, Messenger; Thiazoles; Time Factors	2012
Overactive bladder, under scrutiny, gets a new treatment. Nature medicine, 2012, Volume: 18, Issue:8 Topics: Acetanilides; Adrenergic beta-Agonists; Drug Approval; Humans; Receptors, Adrenergic, beta-3; Thiazoles; United States; United States Food and Drug Administration; Urinary Bladder, Overactive	2012
Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. European urology, 2012, Volume: 62, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Female; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Neurons, Afferent; Rats; Rats, Sprague-Dawley; Thiazoles; Urinary Bladder	2012
Mirabegron for overactive bladder. The Nurse practitioner, 2012, Dec-10, Volume: 37, Issue:12 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Interactions; Humans; Thiazoles; Urinary Bladder, Overactive	2012
Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns. European urology, 2013, Volume: 63, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Benzhydryl Compounds; Cresols; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive	2013
Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Rats; Rats, Wistar; Thiazoles; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder Neck Obstruction	2013
Elvitegravir/cobicistat, mirabegron, and linaclotide. Journal of the American Pharmacists Association : JAPhA, 2012, Volume: 52, Issue:6 Topics: Acetanilides; Adenine; Anti-Retroviral Agents; Carbamates; Constipation; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Peptides; Quinolones; Thiazoles; Urinary Bladder, Overactive	2012
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cerebral Infarction; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Male; Muscle, Smooth; Rats; Rats, Wistar; Receptors, Adrenergic, beta-3; Thiazoles; Transfection; Urinary Bladder; Urinary Bladder, Overactive	2013
The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. European journal of pharmacology, 2013, Jan-15, Volume: 699, Issue:1-3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Carbachol; Humans; In Vitro Techniques; Inhibitory Concentration 50; Isoproterenol; Male; Middle Aged; Muscle Contraction; Thiazoles; Urinary Bladder; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive	2013
Treating overactive bladder: a new tool in your toolkit. Ostomy/wound management, 2012, Volume: 58, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Therapy, Combination; Humans; Thiazoles; Urinary Bladder, Overactive	2012
Drug updates and approvals: 2012 in review. The Nurse practitioner, 2013, Feb-10, Volume: 38, Issue:2 Topics: Acetanilides; Adenine; Antibodies, Monoclonal, Humanized; Benzazepines; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Fatty Alcohols; Humans; Mifepristone; Nicotinic Acids; Nurse Practitioners; Organophosphonates; Phosphatidylglycerols; Prednisone; Proteins; Pyrimidines; Quinolones; Ranibizumab; Tenofovir; Thiazoles; United States; United States Food and Drug Administration	2013
Mirabegron (Myrbetriq) for overactive bladder. The Medical letter on drugs and therapeutics, 2013, Feb-18, Volume: 55, Issue:1410 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Interactions; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics	2013
New drug update: 2012. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2013, Volume: 28, Issue:4 Topics: Acetanilides; Aged; Bronchodilator Agents; Constipation; Drug Approval; Glaucoma; Humans; Peptides; Prostaglandins F; Thiazoles; United States; Urinary Bladder, Overactive	2013
Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Molecular pharmaceutics, 2013, May-06, Volume: 10, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport, Active; Caco-2 Cells; Cell Membrane Permeability; Female; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; LLC-PK1 Cells; Neoplasm Proteins; Oocytes; Organic Anion Transporters; Peptide Transporter 1; Recombinant Proteins; Swine; Symporters; Thiazoles; Urinary Bladder, Overactive; Xenopus laevis	2013
Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Acetanilides; Analysis of Variance; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Data Interpretation, Statistical; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Psychometrics; Quality-Adjusted Life Years; Sickness Impact Profile; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive	2013
Editorial comment. Urology, 2013, Volume: 82, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive	2013
New drugs 2013, part 2. Nursing, 2013, Volume: 43, Issue:7 Topics: Acetanilides; Adrenergic beta-Agonists; Anti-Asthmatic Agents; Anti-Retroviral Agents; Bronchodilator Agents; Citrates; Crotonates; Drug Approval; Humans; Hydroxybutyrates; Immunosuppressive Agents; Laxatives; Nitriles; Organometallic Compounds; Peptides; Picolines; Piperidines; Pyrimidines; Pyrroles; Quinolones; Receptors, Guanylate Cyclase-Coupled; Thiazoles; Toluidines; Tropanes	2013
Lower urinary tract dysfunction: From basic science to clinical management. Foreword. International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Afferent Pathways; Biomarkers; Botulinum Toxins; Carbolines; Humans; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Thiazoles; Urinary Bladder, Overactive; Urothelium	2013
Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; CHO Cells; Cricetulus; Cyclic AMP; Female; In Vitro Techniques; Macaca fascicularis; Muscle Contraction; Muscle, Smooth; Receptors, Adrenergic, beta-3; RNA, Messenger; Thiazoles; Urinary Bladder	2013
Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. European urology, 2013, Volume: 64, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cholesterol, Dietary; Chronic Disease; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Iliac Artery; Ischemia; Male; Neointima; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-3; Thiazoles; Time Factors; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Vascular System Injuries	2013
Mirabegron for male lower urinary tract symptoms. Current urology reports, 2013, Volume: 14, Issue:6 Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Lower Urinary Tract Symptoms; Male; Nocturia; Prostatic Hyperplasia; Prostatism; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2013
Urogynecology digest : presented by Fiona M. Lindo. International urogynecology journal, 2014, Volume: 25, Issue:1 Topics: Acetanilides; Bariatric Surgery; Cystitis, Interstitial; Female; Gynecology; Humans; Muscarinic Antagonists; Obesity; Pelvic Floor Disorders; Thiazoles; Urinary Bladder, Overactive; Urology	2014
Mirabegron for overactive bladder syndrome. Drug and therapeutics bulletin, 2013, Volume: 51, Issue:8 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Humans; Male; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Urge	2013
A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle. The Journal of pharmacology and experimental therapeutics, 2013, Volume: 347, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Female; Muscle Contraction; Perfusion; Rats; Rats, Wistar; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder; Urination	2013
[Efficacy of mirabegron, a β3-adrenergic agonist, switched from an anticholinergic agent for female patients aged over 70 years]. Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:9 Topics: Acetanilides; Adrenergic beta-2 Receptor Agonists; Age Factors; Aged; Aged, 80 and over; Cholinergic Antagonists; Drug Substitution; Female; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2013
Inaccuracies in the recently published review on mirabegron. International urogynecology journal, 2014, Volume: 25, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Thiazoles; Urinary Bladder, Overactive	2014
Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat. Neurourology and urodynamics, 2015, Volume: 34, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Arginine; Electric Stimulation; Female; Mandelic Acids; Mechanotransduction, Cellular; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Nerve Fibers, Myelinated; Nerve Fibers, Unmyelinated; Neurons, Afferent; Nitric Oxide; Periodicity; Pressure; Rats, Sprague-Dawley; Reflex; Thiazoles; Time Factors; Urinary Bladder	2015
ICH E14-compatible holter bin method and its equivalence to individual heart rate correction in the assessment of drug-induced QT changes. Journal of cardiovascular electrophysiology, 2014, Volume: 25, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Long QT Syndrome; Male; Thiazoles	2014
Effect of mirabegron on plasma gonadotropic and steroidal hormone levels in rats after two weeks of oral administration. The Journal of toxicological sciences, 2014, Volume: 39, Issue:3 Topics: Acetanilides; Administration, Oral; Adrenergic beta-Agonists; Animals; Corticosterone; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Estrus; Female; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Luteinizing Hormone; Male; Organ Size; Progesterone; Prolactin; Rats; Rats, Sprague-Dawley; Reproduction; Testosterone; Thiazoles; Time Factors; Urological Agents	2014
Mirabegron the first β3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies. BJU international, 2014, Volume: 113, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive	2014
New treatments for incontinence. Find out which of the latest therapies are worth trying. Harvard women's health watch, 2014, Volume: 21, Issue:7 Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Mandelic Acids; Suburethral Slings; Thiazoles; Transdermal Patch; Urinary Incontinence; Urological Agents	2014
Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy? International urogynecology journal, 2015, Volume: 26, Issue:3 Topics: Acetanilides; Acetylcholine Release Inhibitors; Administration, Intravesical; Adrenergic beta-3 Receptor Agonists; Aged; Botulinum Toxins, Type A; Female; Humans; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Retreatment; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive	2015
Enhancement of 18F-fluorodeoxyglucose metabolism in rat brain frontal cortex using a β3 adrenoceptor agonist. Synapse (New York, N.Y.), 2015, Volume: 69, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Blood-Brain Barrier; Dioxoles; Fluorodeoxyglucose F18; Frontal Lobe; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Thiazoles; Tomography, X-Ray Computed	2015
The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication? The Prostate, 2015, Mar-01, Volume: 75, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Male; Muscle Relaxation; Muscle, Smooth; Prostate; Rabbits; Thiazoles	2015
Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service. Journal of medical economics, 2015, Volume: 18, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cost-Benefit Analysis; Health Services; Humans; Markov Chains; Muscarinic Antagonists; National Health Programs; Thiazoles; United Kingdom; Urinary Bladder, Overactive; Urological Agents	2015
[Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation]. Hinyokika kiyo. Acta urologica Japonica, 2015, Volume: 61, Issue:1 Topics: Acetanilides; Adult; Aged; Cholinergic Antagonists; Diagnostic Imaging; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Radiography; Retrospective Studies; Spinal Cord Diseases; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Neurogenic; Urodynamics	2015
[Idiopathic overactive bladder: What to do in case of anticholinergic failure?]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2015, Volume: 25, Issue:8 Topics: Acetanilides; Acetylcholine Release Inhibitors; Adrenergic beta-3 Receptor Agonists; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Thiazoles; Treatment Failure; Urinary Bladder, Overactive	2015
The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder. European journal of obstetrics, gynecology, and reproductive biology, 2015, Volume: 187 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cohort Studies; Electrocardiography; Female; Heart Rate; Humans; Middle Aged; Risk Factors; Thiazoles; Urinary Bladder, Overactive	2015
Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia. Urology, 2015, Volume: 85, Issue:5 Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive	2015
Mirabegron. British journal of clinical pharmacology, 2015, Volume: 80, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Neuromuscular Agents; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive	2015
Liquid Chromatographic Separation and Thermodynamic Investigation of Mirabegron Enantiomers on a Chiralpak AY-H Column. Journal of chromatographic science, 2015, Volume: 53, Issue:8 Topics: Acetanilides; Amylose; Carbamates; Chromatography, High Pressure Liquid; Ethanol; Limit of Detection; Linear Models; Reproducibility of Results; Stereoisomerism; Thermodynamics; Thiazoles	2015
Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor. European journal of pharmacology, 2015, Jul-05, Volume: 758 Topics: Acetanilides; Acetylcholine; Adrenergic beta-3 Receptor Agonists; Aminophenols; Dose-Response Relationship, Drug; Electric Stimulation; Ethanolamines; Humans; Isoproterenol; Male; Muscle Contraction; Muscle, Smooth; Propanolamines; Receptors, Adrenergic, beta-3; Sulfonamides; Thiazoles; Urinary Bladder	2015
β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase. Naunyn-Schmiedeberg's archives of pharmacology, 2015, Volume: 388, Issue:7 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Amides; Animals; Female; Humans; In Vitro Techniques; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Male; Middle Aged; Muscle Relaxation; Peptides; Phosphorylation; Pyridines; Rats, Wistar; Receptors, Adrenergic, beta-3; rho-Associated Kinases; Species Specificity; Thiazoles; Urinary Bladder	2015
Drugs for urologic disorders. Nursing, 2015, Volume: 45, Issue:6 Topics: Acetanilides; Azasteroids; Drug Combinations; Dutasteride; Ferric Compounds; Gels; Humans; Injections; Maltose; Mandelic Acids; Sulfonamides; Tamsulosin; Thiazoles; Urologic Diseases; Urological Agents	2015
Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder. International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:10 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Cholinergic Antagonists; Compliance; Female; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Radiography; Retreatment; Retrospective Studies; Thiazoles; Urinary Bladder; Urodynamics; Young Adult	2015
Drug therapy for an overactive bladder. Women's health (London, England), 2015, Volume: 11, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Comorbidity; Female; Humans; Medication Adherence; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urological Agents; Women's Health	2015
Urinary Bladder Dysfunction in Transgenic Sickle Cell Disease Mice. PloS one, 2015, Volume: 10, Issue:8 Topics: Acetanilides; Adenosine Triphosphate; Anemia, Sickle Cell; Animals; Atropine; Calcium Chloride; Carbachol; Disease Models, Animal; Diuresis; Electric Stimulation; Hemoglobin, Sickle; Humans; Isoproterenol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle Contraction; Muscle, Smooth; Phenylephrine; Potassium Chloride; Thiazoles; Urethra; Urinary Bladder	2015
[Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study]. Ceska gynekologie, 2015, Volume: 80, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Body Mass Index; Cholinergic Antagonists; Female; Humans; Male; Middle Aged; Patient Compliance; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2015
Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms? International urogynecology journal, 2016, Volume: 27, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Diagnostic Techniques, Urological; Female; Humans; Middle Aged; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2016
Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB. Nature reviews. Urology, 2015, Volume: 12, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Patient Preference; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Xerostomia	2015
Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2015, Volume: 18, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Bayes Theorem; Comparative Effectiveness Research; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Health Resources; Humans; Markov Chains; Models, Economic; Muscarinic Antagonists; Patient Selection; Quality of Life; Quality-Adjusted Life Years; Severity of Illness Index; State Medicine; Thiazoles; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder; Urinary Bladder, Overactive	2015
Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade. British journal of pharmacology, 2016, Volume: 173, Issue:3 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aminophenols; Animals; Aorta, Thoracic; HEK293 Cells; Humans; In Vitro Techniques; Male; Mice, Inbred C57BL; Muscle Relaxation; Muscle, Smooth; Prostate; Rats, Wistar; Receptors, Adrenergic, alpha; Spleen; Sulfonamides; Thiazoles; Urethra; Vas Deferens	2016
Mirabegron: A new option in treating overactive bladder. JAAPA : official journal of the American Academy of Physician Assistants, 2015, Volume: 28, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Humans; Hypertension; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2015
Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal cord, 2016, Volume: 54, Issue:1 Topics: Acetanilides; Adult; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Spinal Cord Injuries; Statistics, Nonparametric; Switzerland; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2016
Persistence with mirabegron therapy for overactive bladder: A real life experience. Neurourology and urodynamics, 2017, Volume: 36, Issue:2 Topics: Acetanilides; Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Male; Middle Aged; Patient Satisfaction; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Young Adult	2017
Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 196 Topics: Acetanilides; Aged; Body Mass Index; Female; Humans; Middle Aged; Risk Factors; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2016
Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. International urogynecology journal, 2016, Volume: 27, Issue:8 Topics: Acetanilides; Adult; Aged; Cholinergic Antagonists; Drug Therapy, Combination; Female; Humans; Medication Adherence; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2016
Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. European urology, 2016, Volume: 70, Issue:1 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Female; Humans; Male; Muscarinic Antagonists; Off-Label Use; Patient Satisfaction; Pilot Projects; Prospective Studies; Retreatment; Surveys and Questionnaires; Thiazoles; Treatment Failure; Urinary Bladder, Overactive; Urinary Incontinence	2016
Bladder telemetry: A new approach to evaluate micturition behavior under physiological and inflammatory conditions. Neurourology and urodynamics, 2017, Volume: 36, Issue:2 Topics: Acetanilides; Animals; Diuretics; Female; Furosemide; Rats; Rats, Sprague-Dawley; Telemetry; Thiazoles; Tolterodine Tartrate; Urinary Bladder; Urination; Urodynamics; Urological Agents	2017
When major trials mean minor efficacy. Prescrire international, 2016, Volume: 25, Issue:167 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Clinical Trials as Topic; Humans; Research Design; Thiazoles; Urinary Incontinence, Urge	2016
mirabegron (BETMIGA⁰). Poorly effective in urge urinary incontinence. Prescrire international, 2016, Volume: 25, Issue:167 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Female; Humans; Pregnancy; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Incontinence, Urge	2016
The efficacy and tolerability of mirabegron in a non-trial clinical setting. European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 200 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Female; Humans; Middle Aged; Prospective Studies; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2016
Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Actas urologicas espanolas, 2016, Volume: 40, Issue:8 Topics: Acetanilides; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Female; Humans; Male; Middle Aged; Spain; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Urge	2016
Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson's disease on DBS (GPi). Parkinsonism & related disorders, 2016, Volume: 27 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Parkinson Disease; Recurrence; Thiazoles	2016
Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction? BJU international, 2016, Volume: 118, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Erectile Dysfunction; Humans; Male; Muscle Relaxation; Penis; Rats; Rats, Sprague-Dawley; Thiazoles	2016
Incontinence: Adding mirabegron to solifenacin improves patient outcomes. Nature reviews. Urology, 2016, Volume: 13, Issue:6 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2016
Re: A Randomized, Controlled Trial of Effectiveness and Safety of Management of OAB Symptoms in Elderly Men and Women with Standard-Dosed Combination of Solifenacin and Mirabegron. The Journal of urology, 2016, Volume: 195, Issue:6 Topics: Acetanilides; Aged; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2016
Mirabegron: hypertension, stroke. Prescrire international, 2016, Volume: 25, Issue:170 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Hypertension; Stroke; Thiazoles; Urinary Incontinence	2016
The actions of isoprenaline and mirabegron in the isolated whole rat and guinea pig bladder. Autonomic neuroscience : basic & clinical, 2016, Volume: 198 Topics: Acetanilides; Animals; Arecoline; Carbachol; Female; Guinea Pigs; In Vitro Techniques; Isoproterenol; Muscarinic Agonists; Muscle Contraction; Rats, Sprague-Dawley; Thiazoles; Urinary Bladder	2016
Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study. European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 203 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cardiovascular Diseases; Cohort Studies; Drug Monitoring; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Outpatient Clinics, Hospital; Prospective Studies; Quality of Life; Risk; Self Report; Severity of Illness Index; Sweden; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2016
Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. Journal of medical economics, 2016, Volume: 19, Issue:12 Topics: Acetanilides; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; Male; Markov Chains; Medicare Part C; Muscarinic Antagonists; Thiazoles; United States; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2016
Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. Basic research in cardiology, 2016, Volume: 111, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Blotting, Western; Disease Models, Animal; Female; Humans; Hypertension, Pulmonary; Immunohistochemistry; Male; Nebivolol; Pulmonary Artery; Random Allocation; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta-3; Swine; Thiazoles; Vascular Resistance; Ventricular Remodeling	2016
Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. European journal of drug metabolism and pharmacokinetics, 2017, Volume: 42, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Contraceptives, Oral, Combined; Digoxin; Double-Blind Method; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Metformin; Thiazoles; Urinary Bladder, Overactive; Warfarin	2017
Combined treatment with a β Neurourology and urodynamics, 2017, Volume: 36, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cold Temperature; Disease Models, Animal; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Inbred SHR; Solifenacin Succinate; Stress, Physiological; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents	2017
Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury. Neurourology and urodynamics, 2017, Volume: 36, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Therapy, Combination; Female; Mandelic Acids; Muscarinic Antagonists; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Thiazoles; Urinary Bladder; Urinary Bladder, Neurogenic; Urination; Urodynamics; Urological Agents	2017
Association between Selective Beta-adrenergic Drugs and Blood Pressure Elevation: Data Mining of the Japanese Adverse Drug Event Report (JADER) Database. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2016, Volume: 136, Issue:7 Topics: Acetanilides; Adrenergic beta-Agonists; Adverse Drug Reaction Reporting Systems; Albuterol; Algorithms; Blood Pressure; Data Mining; Databases as Topic; Female; Humans; Japan; Male; Odds Ratio; Thiazoles	2016
The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC urology, 2016, Jul-29, Volume: 16, Issue:1 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2016
Hormonal influence on the effect of mirabegron treatment for overactive bladder. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:12 Topics: Acetanilides; Aged; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Gonadotropins; Humans; Logistic Models; Middle Aged; Prospective Studies; Testosterone; Thiazoles; Thyroid Hormones; Urinary Bladder, Overactive; Urological Agents	2016
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European urology, 2016, Volume: 70, Issue:5 Topics: Acetanilides; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2016
Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:9 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Budgets; Health Care Costs; Humans; Insurance, Health; Medicare Part C; Middle Aged; Muscarinic Antagonists; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents	2016
Oral Sustained Release of a Hydrophilic Drug Using the Lauryl Sulfate Salt/Complex. Chemical & pharmaceutical bulletin, 2016, Volume: 64, Issue:9 Topics: Acetanilides; Administration, Oral; Drug Liberation; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Molecular Conformation; Salts; Sodium Dodecyl Sulfate; Solubility; Thiazoles	2016
Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder. Lower urinary tract symptoms, 2016, Volume: 8, Issue:3 Topics: Acetanilides; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Patient Safety; Prospective Studies; Sulfonamides; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents	2016
Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice. Neurourology and urodynamics, 2017, Volume: 36, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Body Weight; Carbachol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle Contraction; Muscle, Smooth; Obesity; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urination	2017
High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. Medicine, 2016, Volume: 95, Issue:45 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Drug Substitution; Female; Humans; Male; Muscarinic Antagonists; Patient Satisfaction; Thiazoles; Urinary Bladder, Overactive	2016
Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females. Drug metabolism and pharmacokinetics, 2016, Volume: 31, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Benzhydryl Compounds; Cresols; Drug Interactions; Female; Healthy Volunteers; Humans; Middle Aged; Postmenopause; Thiazoles; Tolterodine Tartrate; Urological Agents	2016
Re: The Efficacy of Mirabegron Additional Therapy for Lower Urinary Tract Symptoms after Treatment with Α1-Adrenergic Receptor Blocker Monotherapy: Prospective Analysis of Elderly Men. The Journal of urology, 2016, Volume: 196, Issue:6 Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Aged; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Receptors, Adrenergic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2016
Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study. Lower urinary tract symptoms, 2018, Volume: 10, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Diabetes Complications; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urological Agents	2018
Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. The Journal of urology, 2017, Volume: 197, Issue:4 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2017
Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder? International urogynecology journal, 2017, Volume: 28, Issue:7 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Humans; Middle Aged; Prospective Studies; Thiazoles; Urinary Bladder, Overactive	2017
Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment? Lower urinary tract symptoms, 2018, Volume: 10, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Analysis of Variance; Drug Substitution; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:1 Topics: Acetanilides; Aged; Benzhydryl Compounds; Cross-Sectional Studies; Drug Utilization; Female; Health Care Costs; Health Expenditures; Humans; Male; Managed Care Programs; Medicare; Muscarinic Antagonists; Retrospective Studies; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents	2017
Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. European journal of obstetrics, gynecology, and reproductive biology, 2017, Volume: 210 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Thiazoles; Urinary Bladder, Overactive; Young Adult	2017
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. European urology, 2017, Volume: 72, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Databases, Factual; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Thiazoles; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urological Agents; Young Adult	2017
Re: Mirabegron Relaxes Urethral Smooth Muscle by a Dual Mechanism Involving β3-Adrenoceptor Activation and α1-Adrenoceptor Blockade. The Journal of urology, 2017, Volume: 197, Issue:3 Pt 1 Topics: Acetanilides; Muscle, Smooth; Receptors, Adrenergic, alpha-1; Thiazoles	2017
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE). The Journal of urology, 2017, Volume: 197, Issue:3 Pt 1 Topics: Acetanilides; Double-Blind Method; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2017
Re: Mirabegron Causes Relaxation of Human and Rat Corpus Cavernosum: Could it be a Potential Therapy for Erectile Dysfunction? The Journal of urology, 2017, Volume: 197, Issue:3 Pt 1 Topics: Acetanilides; Animals; Erectile Dysfunction; Humans; Male; Penis; Rats; Thiazoles	2017
Indirect treatment comparison (ITC) of medical therapies for an overactive bladder. Neurourology and urodynamics, 2017, Volume: 36, Issue:7 Topics: Acetanilides; Cholinergic Antagonists; Humans; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents	2017
[Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care]. Urologiia (Moscow, Russia : 1999), 2016, Issue:1 Topics: Acetanilides; Costs and Cost Analysis; Delivery of Health Care; Humans; Models, Economic; Russia; Thiazoles; Urinary Bladder, Overactive	2016
Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. Journal of medical economics, 2017, Volume: 20, Issue:6 Topics: Acetanilides; Canada; Humans; Medication Adherence; Models, Econometric; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk. Urology, 2017, Volume: 104 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Catheterization; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Muscarinic Antagonists; Prostatic Diseases; Randomized Controlled Trials as Topic; Residual Volume; Risk; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents	2017
A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments. Neurourology and urodynamics, 2018, Volume: 37, Issue:1 Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Male; Muscarinic Antagonists; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. International journal of clinical practice, 2017, Volume: 71, Issue:3-4 Topics: Acetanilides; Adult; Aged; Cholinergic Antagonists; Databases, Factual; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Patient Compliance; Retrospective Studies; Thiazoles; Treatment Refusal; Urinary Bladder, Overactive; Urological Agents	2017
Better Persistence Rates with Mirabegron: Questions Raised. European urology, 2017, Volume: 72, Issue:3 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Thiazoles; Urinary Bladder, Overactive	2017
Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. Journal of pharmacological and toxicological methods, 2017, Volume: 87 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; HEK293 Cells; Humans; Male; Thiazoles; Translational Research, Biomedical	2017
Evaluation of Maltose-Induced Chemical Degradation at the Interface of Bilayer Tablets. Chemical & pharmaceutical bulletin, 2017, Volume: 65, Issue:5 Topics: Acetanilides; Drug Stability; Maltose; Molecular Structure; Solifenacin Succinate; Tablets; Thiazoles	2017
Micturition dysfunction in four-month old ovariectomized rats: Effects of testosterone replacement. Life sciences, 2017, Jun-15, Volume: 179 Topics: Acetanilides; Androgens; Angiotensin II; Animals; Carbachol; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Injections, Intramuscular; Letrozole; Muscle, Smooth; Nitriles; Ovariectomy; Postmenopause; Rats; Rats, Sprague-Dawley; Testosterone; Thiazoles; Triazoles; Urethra; Urination Disorders	2017
The β British journal of pharmacology, 2017, Volume: 174, Issue:16 Topics: 1-Methyl-3-isobutylxanthine; Acetanilides; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Atrial Function; Female; Heart Atria; Humans; Imidazoles; In Vitro Techniques; Male; Middle Aged; Myocardial Contraction; Propanolamines; Receptors, Adrenergic, beta; Thiazoles	2017
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investigative and clinical urology, 2017, Volume: 58, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2017
Pharmacology: Cardiovascular effects of mirabegron. Nature reviews. Urology, 2017, Volume: 14, Issue:10 Topics: Acetanilides; Humans; Receptors, Adrenergic; Thiazoles	2017
Incontinence: Patients prefer combination therapy. Nature reviews. Urology, 2017, Volume: 14, Issue:9 Topics: Acetanilides; Double-Blind Method; Humans; Patient Reported Outcome Measures; Solifenacin Succinate; Thiazoles	2017
Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study. Lower urinary tract symptoms, 2019, Volume: 11, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Long-Term Care; Male; Middle Aged; Product Surveillance, Postmarketing; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2019
American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA). Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:6 Topics: Acetanilides; Administration, Intranasal; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Deamino Arginine Vasopressin; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Hydrogels; Mitomycin; Multicenter Studies as Topic; Nocturia; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urology	2017
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States. Journal of medical economics, 2017, Volume: 20, Issue:12 Topics: Acetanilides; Adult; Aged; Botulinum Toxins, Type A; Female; Health Expenditures; Health Resources; Humans; Insurance Claim Review; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents	2017
Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:8 Topics: Acetanilides; Adult; Drug Interactions; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Sirolimus; Thiazoles	2018
Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:10 Topics: Acetanilides; Adult; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; Urinary Bladder, Overactive	2017
Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database. International journal of clinical practice, 2017, Volume: 71, Issue:10 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cohort Studies; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; United Kingdom; Urinary Bladder, Overactive	2017
N Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:12 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Benzhydryl Compounds; Contraindications, Drug; Drug Therapy, Combination; Female; Humans; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:12 Topics: Acetanilides; Benzhydryl Compounds; Drug Therapy, Combination; Female; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2017
Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:3 Topics: Acetanilides; Adrenergic Agonists; Glucuronides; Glucuronosyltransferase; Humans; Kinetics; Metabolic Clearance Rate; Microsomes, Liver; Morphine; Receptors, Adrenergic; Recombinant Proteins; Thiazoles	2018
Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations? BJU international, 2017, Volume: 120, Issue:4 Topics: Acetanilides; Cholinergic Antagonists; Drug Therapy, Combination; Follow-Up Studies; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics	2017
Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Current medical research and opinion, 2018, Volume: 34, Issue:5 Topics: Acetanilides; Aged; Female; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive	2018
Mirabegron Toxicosis in Dogs: a Retrospective Study. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2018, Volume: 14, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Dog Diseases; Dogs; Erythema; Female; Male; Poison Control Centers; Poisoning; Retrospective Studies; Tachycardia; Thiazoles	2018
Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. The Canadian journal of urology, 2017, Volume: 24, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Antidiuretic Agents; Deamino Arginine Vasopressin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscarinic Antagonists; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urination	2017
Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis. The journal of obstetrics and gynaecology research, 2018, Volume: 44, Issue:3 Topics: Acetanilides; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Retrospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2018
Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Lower urinary tract symptoms, 2019, Volume: 11, Issue:2 Topics: Acetanilides; Aged; Central Nervous System Diseases; Dementia; Female; Humans; Male; Parkinson Disease; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2019
Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. Lower urinary tract symptoms, 2019, Volume: 11, Issue:2 Topics: Acetanilides; Aged; Aged, 80 and over; Female; Human T-lymphotropic virus 1; Humans; Middle Aged; Paraparesis, Tropical Spastic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2019
Investigation of Mechanistic Pathway for Trimethyl Borate Mediated Amidation of (R)-Mandelic Acid for the Synthesis of Mirabegron, an Antimuscarinic Agent. Acta chimica Slovenica, 2018, Volume: 65, Issue:1 Topics: Acetanilides; Amides; Borates; Catalysis; Mandelic Acids; Molecular Structure; Muscarinic Antagonists; Oxidation-Reduction; Solvents; Stereoisomerism; Temperature; Thiazoles	2018
Pleurothotonus (Pisa syndrome) Induced by an Association of Clozapine and Mirabegron. The primary care companion for CNS disorders, 2018, Mar-15, Volume: 20, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Interactions; Dystonia; Female; Humans; Middle Aged; Posture; Thiazoles; Urinary Incontinence	2018
Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. Urology, 2018, Volume: 117 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive	2018
Long-term persistence with mirabegron in a real-world clinical setting. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:5 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Proportional Hazards Models; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Young Adult	2018
Mirabegron, a β European journal of pharmacology, 2018, Jun-15, Volume: 829 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Biological Transport; Calcium; Cyclic AMP; Humans; Platelet Aggregation; Receptors, Adrenergic, beta-3; Thiazoles; Thromboxane B2	2018
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology, 2018, Volume: 117 Topics: Acetanilides; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Databases as Topic; Drug Industry; Drug Prescriptions; Humans; Indoles; Medicare Part D; Practice Patterns, Physicians'; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents; Urology	2018
Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. Neurourology and urodynamics, 2018, Volume: 37, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Benzhydryl Compounds; Canada; Cholinergic Antagonists; Cross-Sectional Studies; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Efficacy and safety of mirabegron, a β Lower urinary tract symptoms, 2019, Volume: 11, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics	2019
Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer? European urology, 2018, Volume: 74, Issue:3 Topics: Acetanilides; Humans; Muscarinic Antagonists; Network Meta-Analysis; Thiazoles; Urinary Bladder, Overactive	2018
A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemporary clinical trials, 2018, Volume: 70 Topics: Acetanilides; Female; Follow-Up Studies; Humans; Male; Muscarinic Antagonists; Prospective Studies; Registries; Research Design; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Re: Long-Term Treatment with the Beta-3 Adrenocepter Agonist, Mirabegron Ameliorates Detrusor Overactivity and Restores Cyclic Adenosine Monophosphate (cAMP) Levels in Obese Mice. The Journal of urology, 2018, Volume: 199, Issue:6 Topics: Acetanilides; Adenosine Monophosphate; Animals; Mice; Mice, Obese; Receptors, Adrenergic; Thiazoles	2018
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:1 Pt 2 Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2019
Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice. International urology and nephrology, 2018, Volume: 50, Issue:7 Topics: Acetanilides; Adult; Aged; Female; Humans; Hypertension; Male; Middle Aged; Patient Dropouts; Quality of Life; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2018
Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. Neurourology and urodynamics, 2018, Volume: 37, Issue:8 Topics: Acetanilides; Benzhydryl Compounds; Canada; Humans; Thiazoles; Urinary Bladder, Overactive	2018
Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatrics & gerontology international, 2018, Volume: 18, Issue:9 Topics: Acetanilides; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multimorbidity; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sex Factors; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Combination Therapy for Overactive Bladder: Who Approves? European urology, 2018, Volume: 74, Issue:4 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2018
Human β3-Adrenoreceptor is Resistant to Agonist-Induced Desensitization in Renal Epithelial Cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 48, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Aquaporin 2; Calcium; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Down-Regulation; Epithelial Cells; Fluorescence Resonance Energy Transfer; Humans; Kidney Tubules, Collecting; Mice; Microscopy, Confocal; Receptors, Adrenergic, beta-3; Receptors, Vasopressin; Signal Transduction; Thiazoles	2018
MORPHOLOGICAL ASSESSMENT OF NO-SYNTHASE DISTRIBUTION IN OVERACTIVE BLADDER AND STRESS URINE INCONTINENCE IN ANIMAL MODELS ADMINISTERED WITH EXPERIMENTAL PHARMACOCORRECTION REGIMENS. Georgian medical news, 2018, Issue:279 Topics: Acetanilides; Animals; Benzilates; Drug Therapy, Combination; Estradiol; Female; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nortropanes; Quercetin; Rats; Testosterone; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Stress	2018
Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism & related disorders, 2018, Volume: 57 Topics: Acetanilides; Aged; Cohort Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction. Journal of cardiovascular translational research, 2018, Volume: 11, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Magnetic Resonance Imaging, Cine; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Random Allocation; Swine; Thiazoles; Ventricular Function, Left; Ventricular Remodeling	2018
Efficacy of mirabegron in medical expulsive therapy. Urolithiasis, 2019, Volume: 47, Issue:3 Topics: Acetanilides; Adult; Female; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Thiazoles; Treatment Outcome; Ureteral Calculi; Urological Agents	2019
Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. Lower urinary tract symptoms, 2019, Volume: 11, Issue:2 Topics: Acetanilides; Aged; Female; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2019
Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate. The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:2 Topics: Acetanilides; Animals; Cyclic AMP; Female; Metabolic Syndrome; Muscle Relaxation; Muscle, Smooth; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Receptors, Adrenergic, beta-3; Signal Transduction; Succinic Acid; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urothelium	2018
Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment? International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:10 Topics: Acetanilides; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Humans; Japan; Markov Chains; Muscarinic Antagonists; Quality of Life; Severity of Illness Index; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2018
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. BMC urology, 2018, Sep-04, Volume: 18, Issue:1 Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Linear Models; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Proportional Hazards Models; Retrospective Studies; Spain; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2018
[Contribution of pharmacological research to the discovery of a first-in-class drug, mirabegron, for the treatment of overactive bladder]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2018, Volume: 152, Issue:3 Topics: Acetanilides; Animals; Humans; Rats; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2018
Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis. Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:1 Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic beta-3 Receptor Agonists; Animals; Caloric Restriction; Diet, High-Fat; Dioxoles; Drug Evaluation, Preclinical; Liver; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Thiazoles	2019
Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:8 Topics: Acetanilides; Butyrylcholinesterase; Cytochrome P-450 CYP3A; Drug Interactions; Fluconazole; Glucuronosyltransferase; Humans; Models, Biological; Reproducibility of Results; Thiazoles	2019
Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases. PloS one, 2018, Volume: 13, Issue:10 Topics: Acetanilides; Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Databases, Factual; Electronic Health Records; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Propensity Score; Retrospective Studies; Risk Factors; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents; Young Adult	2018
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eu European urology, 2019, Volume: 75, Issue:3 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2019
Re: The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study. The Journal of urology, 2018, Volume: 200, Issue:5 Topics: Acetanilides; Female; Humans; Prospective Studies; Thiazoles; Urinary Bladder, Overactive	2018
Re: Efficacy and Safety of Combinations of Mirabegron and Solifenacin Compared with Monotherapy and Placebo in Patients with Overactive Bladder (SYNERGY Study). The Journal of urology, 2018, Volume: 200, Issue:3 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2018
Daptomycin-associated myopathy induced by concomitant administration of mirabegron. Infection, 2019, Volume: 47, Issue:2 Topics: Acetanilides; Anti-Bacterial Agents; Daptomycin; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Muscular Diseases; Staphylococcal Infections; Thiazoles; Urological Agents	2019
Effectiveness of an intervention to optimise the use of mirabegron for overactive bladder: a quasi-experimental study in primary care. The British journal of general practice : the journal of the Royal College of General Practitioners, 2018, Volume: 68, Issue:677 Topics: Acetanilides; Aged; Aged, 80 and over; Controlled Before-After Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Primary Health Care; Spain; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2018
Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World journal of urology, 2019, Volume: 37, Issue:8 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Female; Humans; Male; Pilot Projects; Retrospective Studies; Spinal Dysraphism; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic	2019
Cost-effectiveness of overactive bladder treatments: from the US payer perspective. Journal of comparative effectiveness research, 2019, Volume: 8, Issue:1 Topics: Acetanilides; Botulinum Toxins, Type A; Cholinergic Antagonists; Cost-Benefit Analysis; Electric Stimulation Therapy; Electrodes, Implanted; Health Care Costs; Humans; Middle Aged; Neuromuscular Agents; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents	2019
Editorial Comment to Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:3 Topics: Acetanilides; Humans; Japan; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2019
Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. Lower urinary tract symptoms, 2019, Volume: 11, Issue:2 Topics: Acetanilides; Aged; Female; Humans; Male; Quality of Life; Recurrence; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2019
Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice. Lower urinary tract symptoms, 2019, Volume: 11, Issue:3 Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Lower Urinary Tract Symptoms; Male; Medication Adherence; Middle Aged; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Symptom Assessment; Thiazoles; Time Factors; Urinary Bladder, Overactive; Urological Agents	2019
Mirabegron: A Novel and Promising Medical Expulsive Treatment for Ureteral Stones? Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscle Relaxation; Thiazoles; Ureter; Ureteral Calculi	2019
Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle. Lower urinary tract symptoms, 2019, Volume: 11, Issue:2 Topics: Acetanilides; Adenylyl Cyclase Inhibitors; Aged; Amides; Animals; Carbachol; Cyclic AMP; Female; Humans; Indoles; Isoquinolines; Male; Maleimides; Muscle Relaxation; Muscle, Smooth; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases; Signal Transduction; Sulfonamides; Swine; Thiazoles; Urinary Bladder; Urological Agents	2019
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder. BMC urology, 2019, Jan-21, Volume: 19, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Prospective Studies; Sexual Behavior; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive	2019
Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. World journal of urology, 2019, Volume: 37, Issue:11 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Female; Humans; Lasers, Solid-State; Middle Aged; Prospective Studies; Syndrome; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urologic Surgical Procedures; Vagina	2019
Effect of mirabegron on tight junction molecules in primary cultured rat Sertoli cells. Andrologia, 2019, Volume: 51, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Blood-Testis Barrier; Butadienes; Cells, Cultured; Claudins; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Sertoli Cells; Signal Transduction; Spermatogenesis; Thiazoles; Tight Junctions	2019
Re: Safety and Therapeutic Efficacy of Mirabegron 25 mg in Older Patients with Overactive Bladder and Multiple Comorbidities. The Journal of urology, 2019, Volume: 201, Issue:3 Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Overactive	2019
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients European urology, 2019, Volume: 75, Issue:3 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2019
Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population. Journal of pharmaceutical and biomedical analysis, 2019, Apr-15, Volume: 167 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Child; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Thiazoles	2019
Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. Urologia internationalis, 2019, Volume: 102, Issue:3 Topics: Acetanilides; Administration, Oral; Adult; Aged; Aged, 80 and over; Anxiety; Depression; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2019
Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation. Journal of pharmaceutical and biomedical analysis, 2019, May-10, Volume: 168 Topics: Acetanilides; Acetonitriles; Adrenergic beta-3 Receptor Agonists; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Excipients; Formaldehyde; Hydrogen Cyanide; Limit of Detection; Magnetic Resonance Spectroscopy; Mass Spectrometry; Polyethylene Glycols; Tablets; Thiazoles	2019
Patient utilization survey of mirabegron prescribed for overactive bladder. Investigative and clinical urology, 2019, Volume: 60, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Quality of Life; Self Report; Thiazoles; Urinary Bladder, Overactive; Young Adult	2019
Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. Revista da Associacao Medica Brasileira (1992), 2019, Volume: 65, Issue:2 Topics: Acetanilides; Administration, Intravenous; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Animals; Chromatography, High Pressure Liquid; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry; Thiazoles	2019
Urodynamics as a Prognosticator of Mirabegron Treatment Outcomes. Gynecologic and obstetric investigation, 2019, Volume: 84, Issue:5 Topics: Acetanilides; Adult; Aged; Diagnostic Techniques, Urological; Female; Humans; Middle Aged; Predictive Value of Tests; Prognosis; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents	2019
[Value of mirabegron in the treatment of overactive bladder]. Der Urologe. Ausg. A, 2019, Volume: 58, Issue:4 Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2019
Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice. The Journal of pharmacology and experimental therapeutics, 2019, Volume: 369, Issue:3 Topics: 3T3-L1 Cells; Acetanilides; Adipocytes; Adipocytes, Brown; Animals; Body Weight; Diet, High-Fat; Gene Expression Regulation; Glucose; Homeostasis; Male; Mice; Mice, Obese; Obesity; Thiazoles; Uncoupling Protein 1	2019
Mirabegron, A Selective β3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2021, Volume: 129, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Erectile Dysfunction; Male; Rats; Rats, Sprague-Dawley; Thiazoles	2021
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Biopharmaceutics & drug disposition, 2019, Volume: 40, Issue:5-6 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholinesterase; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Desipramine; Drug Interactions; Female; Gemfibrozil; Glucuronosyltransferase; Humans; Itraconazole; Lorazepam; Male; Middle Aged; Models, Biological; Renal Insufficiency; Thiazoles; Young Adult; Zidovudine	2019
Re: Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study. The Journal of urology, 2019, Volume: 201, Issue:5 Topics: Acetanilides; Humans; Marketing; Thiazoles; Urinary Bladder, Overactive	2019
Overactive bladder - pharmacological treatment. Revista da Associacao Medica Brasileira (1992), 2019, May-02, Volume: 65, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antidepressive Agents; Benzilates; Benzofurans; Brazil; Clinical Decision-Making; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Pyrrolidines; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive	2019
Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 05-28, Volume: 116, Issue:22 Topics: Acetanilides; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Atherosclerosis; Cholesterol, LDL; Lipolysis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Receptors, LDL; Thiazoles; Urological Agents	2019
Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. Journal of clinical pharmacology, 2019, Volume: 59, Issue:11 Topics: Acetanilides; Adult; Benzhydryl Compounds; Cresols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Thiazoles; Urinary Bladder, Overactive	2019
Real-Life Data on Mirabegron in Neurogenic Bladder Dysfunction. Urologia internationalis, 2019, Volume: 103, Issue:2 Topics: Acetanilides; Adult; Aged; Female; Humans; Male; Middle Aged; Retrospective Studies; Thiazoles; Urinary Bladder, Neurogenic; Urological Agents	2019
RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourology and urodynamics, 2019, Volume: 38, Issue:6 Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive	2019
A Nordic registry-based study of drug treatment patterns in overactive bladder patients. Scandinavian journal of urology, 2019, Volume: 53, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Denmark; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Norway; Practice Patterns, Physicians'; Prospective Studies; Pyrrolidines; Registries; Solifenacin Succinate; Sweden; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive	2019
Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response. European journal of pharmacology, 2019, Sep-05, Volume: 858 Topics: Acetanilides; Animals; Arterial Pressure; Cyclic AMP; Cyclic GMP; Gene Expression Regulation; Intracellular Space; Male; Muscle Contraction; Muscle Relaxation; Penile Erection; Penis; Rats; Rats, Wistar; Receptors, Adrenergic, beta; RNA, Messenger; Thiazoles	2019
Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE. International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:9 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Young Adult	2019
Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. International urogynecology journal, 2019, Volume: 30, Issue:12 Topics: Acetanilides; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Reproducibility of Results; Surveys and Questionnaires; Symptom Assessment; Thiazoles; Translations; Treatment Outcome; Turkey; Urinary Bladder, Overactive; Urological Agents; Young Adult	2019
Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury. Lower urinary tract symptoms, 2020, Volume: 12, Issue:1 Topics: Acetanilides; Animals; Disease Models, Animal; Female; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Spinal Cord Injuries; Thiazoles; Urethra; Urinary Bladder; Urological Agents	2020
[Urinary incontinence in geriatric patients: pharmacological Therapy]. Aktuelle Urologie, 2019, Volume: 50, Issue:4 Topics: Acetanilides; Aged; Botulinum Toxins; Cholinesterase Inhibitors; Duloxetine Hydrochloride; Female; Frail Elderly; Humans; Male; Muscarinic Antagonists; Practice Guidelines as Topic; Societies, Medical; Thiazoles; Urinary Incontinence	2019
Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate. Drug design, development and therapy, 2019, Volume: 13 Topics: Acetanilides; Benzhydryl Compounds; Chemistry, Physical; Drug Liberation; Fumarates; Lipid Bilayers; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; Thiazoles	2019
Short-term cold exposure supports human Treg induction in vivo. Molecular metabolism, 2019, Volume: 28 Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic beta-Agonists; Adult; Animals; Cold Temperature; Female; Humans; Male; Mice; Middle Aged; Receptors, Adrenergic, beta; T-Lymphocytes, Regulatory; Thiazoles; Young Adult	2019
Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. Journal of the Chinese Medical Association : JCMA, 2020, Volume: 83, Issue:1 Topics: Acetanilides; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Penile Erection; Prospective Studies; Thiazoles; Urinary Bladder, Overactive	2020
The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction. World journal of urology, 2020, Volume: 38, Issue:8 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Female; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Thiazoles; Urinary Bladder; Urinary Bladder Neck Obstruction	2020
Treatment of Elderly Patients with Overactive Bladder: Has Mirabegron Come of Age? European urology, 2020, Volume: 77, Issue:2 Topics: Acetanilides; Aged; Double-Blind Method; Humans; Thiazoles; Urinary Bladder, Overactive	2020
Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies. Lower urinary tract symptoms, 2020, Volume: 12, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Disease Models, Animal; Drug Monitoring; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Sprague-Dawley; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. Journal of pediatric urology, 2020, Volume: 16, Issue:1 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Cohort Studies; Female; Humans; Male; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive	2020
Re: Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE. International journal of urology : official journal of the Japanese Urological Association, 2020, Volume: 27, Issue:2 Topics: Acetanilides; Aged; Europe; Humans; Quality of Life; Thiazoles; Urinary Bladder, Overactive	2020
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways. Pharmacology, biochemistry, and behavior, 2020, Volume: 189 Topics: Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Duloxetine Hydrochloride; Female; Locomotion; Rats; Rats, Wistar; Signal Transduction; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Exploratory analysis of the effect of mirabegron on urodynamic sensation parameters and urethral pressure variations. International urogynecology journal, 2021, Volume: 32, Issue:1 Topics: Acetanilides; Adult; Female; Humans; Prospective Studies; Sensation; Thiazoles; Urinary Bladder, Overactive; Urodynamics	2021
Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis. Pharmacology research & perspectives, 2020, Volume: 8, Issue:1 Topics: Acetanilides; Animals; Cyclophosphamide; Cystitis; Disease Models, Animal; Drug Therapy, Combination; Male; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive	2020
Mirabegron improves sleep measures, nocturia, and lower urinary tract symptoms in those with urinary symptoms associated with disordered sleep. The Canadian journal of urology, 2020, Volume: 27, Issue:1 Topics: Acetanilides; Aged; Female; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nocturia; Prospective Studies; Sleep; Sleep Wake Disorders; Thiazoles; Treatment Outcome	2020
Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder. International urology and nephrology, 2020, Volume: 52, Issue:6 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Female; Humans; Italy; Medication Adherence; Middle Aged; Prospective Studies; Thiazoles; Urinary Bladder, Overactive	2020
Quality of life and treatment persistence evaluation in Spanish patients treated with mirabegron. Results of the BELIEVE study. Actas urologicas espanolas, 2020, Volume: 44, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies; Self Report; Spain; Thiazoles; Urinary Bladder, Overactive	2020
Editorial Comment. The Journal of urology, 2020, Volume: 203, Issue:6 Topics: Acetanilides; Humans; Male; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Urinary Bladder, Overactive	2020
Might β3-adrenergic receptor agonists be useful in disorders of glucose homeostasis? The Journal of clinical investigation, 2020, 05-01, Volume: 130, Issue:5 Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Cholesterol, HDL; Glucose; Homeostasis; Humans; Insulin Resistance; Thiazoles	2020
Medications used to treat bladder disorders may alter effects of neuromodulation. Neurourology and urodynamics, 2020, Volume: 39, Issue:5 Topics: Acetanilides; Animals; Cystitis; Electric Stimulation Therapy; Female; Mandelic Acids; Muscle Contraction; Pudendal Nerve; Rats; Rats, Sprague-Dawley; Thiazoles; Urological Agents	2020
The Efficacy of Mirabegron for the Relief of Ureteral Stent-Related Symptoms. Acta medica Okayama, 2020, Volume: 74, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Lithotripsy; Male; Middle Aged; Prospective Studies; Quality of Life; Stents; Thiazoles; Urinary Bladder, Overactive; Urinary Calculi	2020
Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder. International journal of clinical practice, 2020, Volume: 74, Issue:9 Topics: Acetanilides; Aged; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
FDG Uptake in Brown Adipose Tissue Activated by a β3-Adrenergic Receptor Agonist Prescribed for Overactive Bladder. Clinical nuclear medicine, 2020, Volume: 45, Issue:8 Topics: Acetanilides; Adipose Tissue, Brown; Adrenal Gland Neoplasms; Adrenergic Agonists; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Thiazoles; Urinary Bladder, Overactive	2020
Validated spectrofluorimetric method for determination of mirabegron by utilizing its quenching effect on acetoxymercuric fluorescein reagent. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Oct-05, Volume: 239 Topics: Acetanilides; Fluorescein; Hydrogen-Ion Concentration; Indicators and Reagents; Spectrometry, Fluorescence; Tablets; Thiazoles	2020
[Analysis of costs and consequences related to the persistence of Mirabegron and antimuscarinic treatments and their impact on quality of life in patients with overactive bladder in Spain: Results of a probabilistic model.] Archivos espanoles de urologia, 2020, Volume: 73, Issue:6 Topics: Acetanilides; Humans; Models, Statistical; Muscarinic Antagonists; Quality of Life; Spain; Thiazoles; Urinary Bladder, Overactive	2020
Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study. Investigative and clinical urology, 2020, Volume: 61, Issue:4 Topics: Acetanilides; Adrenergic alpha-Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2020
Aktuelle Urologie, 2020, Volume: 51, Issue:4 Topics: Acetanilides; Child; Humans; Spinal Dysraphism; Thiazoles	2020
Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study. Lower urinary tract symptoms, 2021, Volume: 13, Issue:1 Topics: Acetanilides; Aged; Female; Humans; Male; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2021
Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. Journal of pediatric urology, 2020, Volume: 16, Issue:5 Topics: Acetanilides; Adolescent; Child; Humans; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics	2020
The metabolic effects of mirabegron are mediated primarily by β Pharmacology research & perspectives, 2020, Volume: 8, Issue:5 Topics: Acetanilides; Adenosine Monophosphate; Adipocytes, Beige; Adipocytes, Brown; Adrenergic beta-3 Receptor Agonists; Animals; Cells, Cultured; CHO Cells; Cricetulus; Deoxyglucose; Gene Knockout Techniques; Glycolysis; Male; Mice; Oxygen; Thiazoles; Uncoupling Protein 1	2020
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. Neurourology and urodynamics, 2020, Volume: 39, Issue:8 Topics: Acetanilides; Adult; Aged; Botulinum Toxins, Type A; Combined Modality Therapy; Electric Stimulation Therapy; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; Tibial Nerve; United States; Urinary Bladder, Overactive	2020
A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study). Neurourology and urodynamics, 2020, Volume: 39, Issue:8 Topics: Acetanilides; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Prospective Studies; Retreatment; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2020
Overactive bladder medication: Persistence, drug switching, and reinitiation. Neurourology and urodynamics, 2020, Volume: 39, Issue:8 Topics: Acetanilides; Adult; Aged; Drug Substitution; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Cost-Effectiveness Analysis and Budget Impact: Antimuscarinics and Mirabegron for the Treatment of Patients With Urge Urinary Incontinence: The Brazilian Public Health System Perspective. Value in health regional issues, 2020, Volume: 23 Topics: Acetanilides; Adult; Brazil; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Public Health; Thiazoles; Urinary Incontinence, Urge; Urological Agents	2020
The application of extreme value theory to pharmacometrics. Journal of pharmacokinetics and pharmacodynamics, 2021, Volume: 48, Issue:1 Topics: Acetanilides; Cross-Over Studies; Data Interpretation, Statistical; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Female; Heart Rate; Humans; Male; Minimal Clinically Important Difference; Models, Biological; Moxifloxacin; Pharmacology, Clinical; Placebos; Randomized Controlled Trials as Topic; Thiazoles	2021
Re: Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. The Journal of urology, 2020, Volume: 204, Issue:6 Topics: Acetanilides; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive	2020
Role of β Bulletin of experimental biology and medicine, 2020, Volume: 169, Issue:6 Topics: Acetanilides; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Capillary Permeability; Disease Models, Animal; Isoproterenol; Lung; Nebivolol; Propranolol; Pulmonary Circulation; Pulmonary Embolism; Rabbits; Receptors, Adrenergic, beta; Thiazoles; Vascular Resistance	2020
Effects of mirabegron on JJ stent-related symptoms: A multicentric study. International journal of clinical practice, 2021, Volume: 75, Issue:2 Topics: Acetanilides; Humans; Quality of Life; Retrospective Studies; Stents; Surveys and Questionnaires; Thiazoles; Ureter	2021
"First, Do No Harm"-Trainees' Observation of Risk Reduction in the Treatment of Overactive Bladder. Female pelvic medicine & reconstructive surgery, 2021, 01-01, Volume: 27, Issue:1 Topics: Acetanilides; Aged; Cholinergic Antagonists; Dementia; Female; Humans; Insurance Coverage; Middle Aged; Risk; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2021
Re: "Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study". Lower urinary tract symptoms, 2021, Volume: 13, Issue:1 Topics: Acetanilides; Prospective Studies; Stents; Tamsulosin; Thiazoles	2021
Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study. Neurourology and urodynamics, 2021, Volume: 40, Issue:2 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Humans; Male; Prospective Studies; Spinal Cord Injuries; Thiazoles; Urinary Bladder, Overactive	2021
Body-weight-independent glucose-lowering effect of the β3-adrenergic receptor agonist mirabegron in humans. Journal of diabetes investigation, 2021, Volume: 12, Issue:5 Topics: Acetanilides; Adrenergic Agonists; Glucose; Humans; Thiazoles	2021
Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an Oral Drug Delivery for Overactive Bladder. Pharmaceutical nanotechnology, 2021, Volume: 9, Issue:2 Topics: Acetanilides; Animals; Drug Delivery Systems; Lipids; Nanoparticles; Pharmaceutical Preparations; Rats; Rats, Wistar; Thiazoles; Urinary Bladder, Overactive	2021
Comment on "A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)". Neurourology and urodynamics, 2021, Volume: 40, Issue:2 Topics: Acetanilides; Humans; Muscarinic Antagonists; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Thiazoles; Urinary Bladder, Overactive	2021
Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism. JCI insight, 2021, 03-22, Volume: 6, Issue:6 Topics: Acetanilides; Adipose Tissue, Beige; Drug Synergism; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Obesity; Pioglitazone; Thiazoles	2021
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Current medical research and opinion, 2021, Volume: 37, Issue:5 Topics: Acetanilides; Female; Humans; Male; Muscarinic Antagonists; Neoplasms; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Mirabegron Alleviates the Degree of Burden Experienced by Caregivers of Older Females with Mixed or Urge Incontinence: A Prospective Study. Clinical interventions in aging, 2021, Volume: 16 Topics: Acetanilides; Aged; Caregiver Burden; Caregivers; Female; Humans; Outcome Assessment, Health Care; Pilot Projects; Quality of Life; Surveys and Questionnaires; Thiazoles; Urinary Incontinence; Urological Agents	2021
Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder. The Journal of pharmacology and experimental therapeutics, 2021, Volume: 377, Issue:2 Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Animals; Brain; Male; Muscarinic Antagonists; Muscle Contraction; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Submandibular Gland; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents	2021
Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β European journal of pharmacology, 2021, May-15, Volume: 899 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Calcium Signaling; Cyclic AMP; Disease Models, Animal; Drug Therapy, Combination; Female; HEK293 Cells; Humans; Muscarinic Antagonists; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-3; Thiazoles; Tolterodine Tartrate; TRPM Cation Channels; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics	2021
Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study. Investigative and clinical urology, 2021, Volume: 62, Issue:3 Topics: Acetanilides; Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Male; Retrospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Does mirabegron deteriorate spermatogenesis? A lesson from spinal cord injury cases. Lower urinary tract symptoms, 2021, Volume: 13, Issue:4 Topics: Acetanilides; Adult; Animals; Humans; Male; Middle Aged; Spermatogenesis; Spinal Cord Injuries; Thiazoles; Young Adult	2021
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Lower urinary tract symptoms, 2021, Volume: 13, Issue:4 Topics: Acetanilides; Adult; Humans; Muscarinic Antagonists; Prospective Studies; Registries; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan. Lower urinary tract symptoms, 2021, Volume: 13, Issue:4 Topics: Acetanilides; Hospitals; Humans; Japan; Pyrimidinones; Pyrrolidines; Retrospective Studies; Thiazoles; Treatment Outcome	2021
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study. Neurourology and urodynamics, 2021, Volume: 40, Issue:6 Topics: Acetanilides; Adolescent; Adult; Child; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics	2021
The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy. Spinal cord series and cases, 2021, 06-10, Volume: 7, Issue:1 Topics: Acetanilides; Aged; Aged, 80 and over; Cholinergic Antagonists; Cognition; Humans; Pilot Projects; Spinal Cord Injuries; Thiazoles; Urinary Bladder, Overactive	2021
Mirabegron safe and effective for NDO. Nature reviews. Urology, 2021, Volume: 18, Issue:8 Topics: Acetanilides; Humans; Thiazoles	2021
Mirabegron Ameliorated Atherosclerosis of ApoE Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:5 Topics: Acetanilides; Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Humans; Hypoxia; Mice; Oxygen; Reactive Oxygen Species; Receptors, Adrenergic; Sleep Apnea, Obstructive; Thiazoles	2022
Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study. International journal of impotence research, 2022, Volume: 34, Issue:6 Topics: Acetanilides; Adult; Aged; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pilot Projects; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2022
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug safety, 2021, Volume: 44, Issue:8 Topics: Acetanilides; Aged; Cardiovascular Diseases; Cohort Studies; Female; Heart Disease Risk Factors; Humans; Male; Muscarinic Antagonists; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2021
Evaluation of the Effect of a Novel β3-Adrenergic Agonist on Choroidal Vascularity. Investigative ophthalmology & visual science, 2021, 07-01, Volume: 62, Issue:9 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Choroid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Retinal Vessels; Thiazoles; Tomography, Optical Coherence; Visual Acuity	2021
Effects of β3-adrenoceptor agonist on acute urinary retention in a rat model. World journal of urology, 2021, Volume: 39, Issue:12 Topics: Acetanilides; Acute Disease; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Rats; Rats, Sprague-Dawley; Thiazoles; Urinary Retention	2021
Cryo-EM structure of the β3-adrenergic receptor reveals the molecular basis of subtype selectivity. Molecular cell, 2021, 08-05, Volume: 81, Issue:15 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Binding Sites; Cryoelectron Microscopy; Dogs; Humans; Models, Molecular; Molecular Dynamics Simulation; Receptors, Adrenergic, beta-3; Thiazoles	2021
Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy. Scientific reports, 2021, 09-01, Volume: 11, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Antihypertensive Agents; Cardiomyopathies; Losartan; Male; Nephrectomy; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Thiazoles; Uremia	2021
The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study. BMC urology, 2021, Sep-02, Volume: 21, Issue:1 Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; United Kingdom; Urological Agents; Young Adult	2021
Mirabegron has longer treatment persistence than antimuscarinics: Real-world data from a Korean national cohort database. Neurourology and urodynamics, 2021, Volume: 40, Issue:8 Topics: Acetanilides; Adult; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2021
Pharmacotherapy of patients with benign prostate enlargement and storage symptoms in everyday clinical practice. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:16 Topics: Acetanilides; Adrenergic alpha-Antagonists; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Cohort Studies; Decision Trees; Guideline Adherence; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Thiazoles	2021
The effect of Mirabegron and Duloxetine combination in mixed-type urinary incontinence treatment. Revista da Associacao Medica Brasileira (1992), 2021, Volume: 67, Issue:5 Topics: Acetanilides; Double-Blind Method; Duloxetine Hydrochloride; Humans; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2021
Editorial Comment to Efficacy of mirabegron, a β International journal of urology : official journal of the Japanese Urological Association, 2022, Volume: 29, Issue:1 Topics: Acetanilides; Double-Blind Method; Female; Humans; Japan; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence	2022
Transcutaneous electrical nerve stimulation as add-on therapy in children receiving anticholinergics and/or mirabegron for refractory daytime urinary incontinence: A retrospective cohort study. Neurourology and urodynamics, 2022, Volume: 41, Issue:1 Topics: Acetanilides; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Diurnal Enuresis; Humans; Retrospective Studies; Thiazoles; Transcutaneous Electric Nerve Stimulation; Treatment Outcome; Urinary Bladder, Overactive	2022
Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study. Pediatric surgery international, 2022, Volume: 38, Issue:3 Topics: Acetanilides; Child; Humans; Pilot Projects; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics	2022
Effects of mirabegron on depression, anxiety, learning and memory in mice. Anais da Academia Brasileira de Ciencias, 2021, Volume: 93, Issue:suppl 4 Topics: Acetanilides; Aged; Animals; Anxiety; Depression; Humans; Maze Learning; Mice; Thiazoles	2021
Inhibition of Full Smooth Muscle Contraction in Isolated Human Detrusor Tissues by Mirabegron Is Limited to Off-Target Inhibition of Neurogenic Contractions. The Journal of pharmacology and experimental therapeutics, 2022, Volume: 381, Issue:2 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetanilides; Carbachol; Endothelin-1; Female; Humans; Male; Methacholine Chloride; Muscle Contraction; Muscle, Smooth; Receptors, Adrenergic; Thiazoles; Urinary Bladder, Overactive	2022
Cold Exposure Drives Weight Gain and Adiposity following Chronic Suppression of Brown Adipose Tissue. International journal of molecular sciences, 2022, Feb-07, Volume: 23, Issue:3 Topics: Acetanilides; Adipose Tissue, Brown; Animals; Cold Temperature; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Male; Proteomics; Rats; Subcutaneous Fat; Thermogenesis; Thiazoles; Uncoupling Protein 1; Weight Gain	2022
Activating Human Adipose Tissue with the β3-Adrenergic Agonist Mirabegron. Methods in molecular biology (Clifton, N.J.), 2022, Volume: 2448 Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic beta-Agonists; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Thiazoles	2022
Overactive bladder medication: Anticholinergics versus mirabegron by specialty. Urologia, 2022, Volume: 89, Issue:4 Topics: Acetanilides; Aged; Cholinergic Antagonists; Humans; Medicare; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents	2022
Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model. International journal of molecular sciences, 2022, Feb-16, Volume: 23, Issue:4 Topics: Acetanilides; Animals; Cardiomyopathies; Cardiotoxicity; Doxorubicin; Losartan; Male; Rats; Rats, Wistar; Thiazoles	2022
Effects of chronic mirabegron treatment on metabolic and cardiovascular parameters as well as on atherosclerotic lesions of WHHL rabbits with high-fructose high-fat diet-induced insulin resistance. European journal of pharmacology, 2022, Apr-15, Volume: 921 Topics: Acetanilides; Animals; Atherosclerosis; Blood Glucose; Diet, High-Fat; Fructose; Insulin; Insulin Resistance; Rabbits; Thiazoles	2022
Resource use and healthcare costs in patients with overactive bladder who initiate treatment with mirabegron or antimuscarinic monotherapy in Catalonia: the MIRACAT study. Actas urologicas espanolas, 2022, Volume: 46, Issue:3 Topics: Acetanilides; Adult; Female; Health Care Costs; Humans; Male; Muscarinic Antagonists; Quality of Life; Retrospective Studies; Spain; Thiazoles; Urinary Bladder, Overactive; Urological Agents	2022
Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC urology, 2022, Mar-21, Volume: 22, Issue:1 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged, 80 and over; Female; Frail Elderly; Humans; Japan; Male; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2022
Re: Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study. Pediatric surgery international, 2022, Volume: 38, Issue:6 Topics: Acetanilides; Child; Female; Humans; Male; Pilot Projects; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive	2022
Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women. International urogynecology journal, 2022, Volume: 33, Issue:5 Topics: Acetanilides; Adult; Aged; Female; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents	2022
Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism. Naunyn-Schmiedeberg's archives of pharmacology, 2022, Volume: 395, Issue:7 Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Muscle Contraction; Phenylephrine; Receptors, Adrenergic, alpha-1; Serotonin; Swine; Thiazoles	2022
Continuous administration of mirabegron has advantages in inhibition of central sensitization compared with short-term treatment cessation in a mouse model of overactive bladder. Neurourology and urodynamics, 2022, Volume: 41, Issue:6 Topics: Acetanilides; Animals; Central Nervous System Sensitization; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiazoles; Urinary Bladder, Overactive	2022
Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. Medicina (Kaunas, Lithuania), 2022, Jun-19, Volume: 58, Issue:6 Topics: Acetanilides; Aged; Blood Pressure; Heart Rate; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2022
Unique liquid chromatography technique for the determination of mirabegron in the presence of polymers; robustness by Design Expert in the light of Quality by Design. Biomedical chromatography : BMC, 2022, Volume: 36, Issue:10 Topics: Acetanilides; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Polymers; Reproducibility of Results; Thiazoles	2022
Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions. European journal of drug metabolism and pharmacokinetics, 2022, Volume: 47, Issue:5 Topics: Acetanilides; Cinacalcet; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Humans; Models, Biological; Nebivolol; Thiazoles	2022
Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice. Scientific reports, 2022, 07-20, Volume: 12, Issue:1 Topics: Acetanilides; Animals; Carbachol; Female; Mice; Muscarinic Antagonists; Solifenacin Succinate; Stress, Psychological; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2022
Mirabegron relaxes arteries from human visceral adipose tissue through antagonism of α Vascular pharmacology, 2022, Volume: 146 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetanilides; Adrenergic Agonists; Arteries; Glucose; Humans; Intra-Abdominal Fat; Phenylephrine; Receptors, Adrenergic, alpha-1; Thiazoles	2022
Vibegron for the treatment of overactive bladder: a comprehensive update. Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:13 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Receptors, Adrenergic, beta-3; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence	2022